{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":84,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":84,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"9ccf8b315765","filters":{"venue":"Therapeutic Advances in Medical Oncology"}},"results":[{"id":"W2111842868","doi":"10.1177/1758834011422556","title":"An overview of the c-MET signaling pathway","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":864,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Signal transduction; Hepatocyte growth factor; Receptor tyrosine kinase; Cancer research; Medicine; Tyrosine kinase; Cell biology; C-Met; Motility; Receptor; Biology; Internal medicine","authors":[{"name":"Shawna Organ","is_ca":true},{"name":"Ming‐Sound Tsao","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1090998566900658,"gpt":0.4107995393709702,"spread":0.3016996826809044,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002184411,0.0007463376,0.0004994565,0.001962649,0.00029933,0.0009552999,0.0004972038,0.0007591083,0.005642754],"category_scores_gemma":[0.0001933868,0.0002333442,0.0003782712,0.001605185,0.0001584892,0.001083635,0.0004487571,0.001196242,0.003511268],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005834458,"about_ca_system_score_gemma":0.0008652119,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001067934,"about_ca_topic_score_gemma":0.001426612,"domain_scores_codex":[0.9998541,0.00001689082,0.00001696615,0.00002273681,0.00006494605,0.00002435384],"domain_scores_gemma":[0.9999146,0.00001834121,0.00001073328,0.000002674463,0.0000308837,0.00002278316],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002811533,0.0001366536,0.0006188526,0.004384615,0.00006061179,0.0008134973,0.00005978293,0.00119012,0.02452771,0.006482165,0.04145153,0.9199933],"study_design_scores_gemma":[0.00001580621,0.0001833733,0.001156894,0.0006985296,0.00005362753,0.002814903,0.00005048739,0.0004356041,0.003557294,0.003422983,0.9875907,0.00001981104],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00273409,0.9673305,0.005720564,0.001862441,0.000902143,0.00004160123,0.0002737348,0.0001537571,0.02098111],"genre_scores_gemma":[0.005928737,0.9783742,0.005632007,0.0006693278,0.0007923081,0.00003793255,0.000442818,0.00001282421,0.008109881],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005642754,"threshold_uncertainty_score":0.01887685,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2122895515","doi":"10.1177/1758834011422557","title":"c-MET as a potential therapeutic target and biomarker in cancer","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":362,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Hepatocyte growth factor; C-Met; Cancer research; Receptor tyrosine kinase; Cabozantinib; Angiogenesis; Tyrosine kinase; Cancer; Targeted therapy; Oncology; Internal medicine; Receptor; VEGF receptors","authors":[{"name":"J. Rafael Sierra","is_ca":true},{"name":"Ming‐Sound Tsao","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04271645134954376,"gpt":0.3864415472270487,"spread":0.3437250958775049,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000626042,0.000337207,0.0005590536,0.0009145443,0.0001582271,0.0007016965,0.0003780044,0.0008746805,0.001185466],"category_scores_gemma":[0.0005488013,0.000107589,0.0001464883,0.0007280938,0.000437917,0.0006264595,0.0003045747,0.0006881517,0.000403217],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005294626,"about_ca_system_score_gemma":0.000547794,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004434879,"about_ca_topic_score_gemma":0.0006100278,"domain_scores_codex":[0.9998048,0.00006759277,0.00001459279,0.00002261493,0.00007020563,0.0000203259],"domain_scores_gemma":[0.9998222,0.00007306167,0.00003365778,0.000006546155,0.00003605749,0.00002843905],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001090335,0.0002033915,0.006747376,0.004241791,0.00008612854,0.002651178,0.0001308122,0.001789836,0.1469673,0.02206151,0.01131212,0.8027183],"study_design_scores_gemma":[0.000214413,0.004555997,0.02681405,0.001751039,0.0004022646,0.02410129,0.0003917682,0.01143473,0.1752138,0.02775478,0.7272213,0.0001445387],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02202173,0.9597341,0.005317568,0.005200427,0.0005753123,0.000033472,0.00008187507,0.00006697377,0.006968434],"genre_scores_gemma":[0.3557951,0.6168975,0.01652815,0.002126561,0.002086367,0.00007096607,0.0002523615,0.00001998638,0.006222979],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001185466,"threshold_uncertainty_score":0.003965795,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139562398","doi":"10.1177/1758834010395342","title":"Health-related quality of life and cancer clinical trials","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Clinical trial; Cancer; Quality of life (healthcare); Quality (philosophy); Intensive care medicine; Oncology; Internal medicine; Nursing","authors":[{"name":"David Osoba","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.299585135842967,"gpt":0.554391340122369,"spread":0.254806204279402,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.1959194,0.001297039,0.007796485,0.004698624,0.001424111,0.008147531,0.002366489,0.008445891,0.0204227],"category_scores_gemma":[0.466908,0.0005809762,0.004676151,0.0142415,0.004126196,0.005137115,0.003381894,0.007607936,0.002723699],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007863929,"about_ca_system_score_gemma":0.009429486,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001408186,"about_ca_topic_score_gemma":0.001088586,"domain_scores_codex":[0.583081,0.3632734,0.02573179,0.007732948,0.01779451,0.002386499],"domain_scores_gemma":[0.3689333,0.5232136,0.07538163,0.01023313,0.01539706,0.006841314],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.04607165,0.001449502,0.04350242,0.1964848,0.04203283,0.0003621423,0.0009134574,0.004896102,0.0001710315,0.07556467,0.1266856,0.4618658],"study_design_scores_gemma":[0.04695157,0.01774633,0.09040885,0.2086909,0.02323074,0.001402584,0.001434106,0.007818284,0.0004414062,0.2505524,0.3506208,0.0007020451],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.006718645,0.9283584,0.004505191,0.03274163,0.005791929,0.002912074,0.003123592,0.00009201995,0.01575651],"genre_scores_gemma":[0.3633525,0.4813778,0.01970608,0.06455564,0.01519719,0.04146266,0.007231333,0.0003433157,0.006773545],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1959194,"threshold_uncertainty_score":0.9915745,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2086837512","doi":"10.1177/1758834012475152","title":"Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects","year":2013,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":166,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Triple-negative breast cancer; Medicine; Breast cancer; Immunotherapy; Immune system; Cancer research; Immune checkpoint; Tumor-infiltrating lymphocytes; Estrogen receptor; Cancer; Immunology; Oncology; Internal medicine","authors":[{"name":"John Stagg","is_ca":true},{"name":"Bertrand Allard","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08073664781397404,"gpt":0.4189070756368191,"spread":0.3381704278228451,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002350322,0.0007035402,0.001215987,0.0008457973,0.0002472838,0.001377983,0.0006950675,0.001463078,0.001783602],"category_scores_gemma":[0.00113595,0.0002277187,0.000613889,0.0010632,0.0008696528,0.001691222,0.0005923124,0.002280122,0.0006703885],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004182174,"about_ca_system_score_gemma":0.0006231127,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003097677,"about_ca_topic_score_gemma":0.0008897939,"domain_scores_codex":[0.9996853,0.00008521324,0.00004529578,0.00004359847,0.00008486871,0.00005583338],"domain_scores_gemma":[0.9991516,0.0004876111,0.0001002842,0.00002995274,0.0001428536,0.000087787],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004886143,0.0006518813,0.0007282401,0.00453364,0.00009901256,0.0003869683,0.0001212284,0.0008011368,0.008761547,0.003559869,0.00984991,0.970018],"study_design_scores_gemma":[0.0009870514,0.008163874,0.01059342,0.01116967,0.0008818535,0.008043037,0.000879085,0.00295586,0.01187378,0.01707218,0.9272566,0.0001235926],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001597348,0.9949297,0.00060379,0.001595867,0.0001692629,0.00001326531,0.00001296586,0.00001536199,0.001062395],"genre_scores_gemma":[0.008719054,0.9878929,0.001312943,0.00101291,0.0005806561,0.00003161147,0.00004357504,0.000005644133,0.000400655],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002350322,"threshold_uncertainty_score":0.01242983,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379508645","doi":"10.1177/17588359231178125","title":"Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy <i>versus</i> endocrine therapy alone in patients with HR+/HER2− early breast cancer","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Genentech; PharmaMar; Novartis Institutes for BioMedical Research; Daewoong Pharmaceutical Company; Astellas Pharma; Eisai; Seagen; Mersana Therapeutics; Mylan; Syndax Pharmaceuticals; Clovis Oncology; Astex Pharmaceuticals; Merck KGaA; Taiho Pharmaceutical; F. Hoffmann-La Roche; Amgen; Radius Health; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Exelixis; Sanofi; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Letrozole; Internal medicine; Breast cancer; Clinical endpoint; Oncology; Anastrozole; Palbociclib; Metastatic breast cancer; Goserelin; Randomization; Cancer; Adjuvant therapy; Clinical trial; Tamoxifen; Gynecology","authors":[{"name":"Dennis J. Slamon","is_ca":false},{"name":"Peter A. Fasching","is_ca":false},{"name":"Sara A. Hurvitz","is_ca":false},{"name":"Stephen Chia","is_ca":true},{"name":"John Crown","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Carlos H. Barrios","is_ca":false},{"name":"Aditya Bardia","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Denise A. Yardley","is_ca":false},{"name":"Michael Untch","is_ca":false},{"name":"Chiun‐Sheng Huang","is_ca":false},{"name":"Daniil Stroyakovskiy","is_ca":false},{"name":"Binghe Xu","is_ca":false},{"name":"Rebecca Moroose","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"F. Visco","is_ca":false},{"name":"Valerie Bee-Munteanu","is_ca":false},{"name":"Karen Afenjar","is_ca":false},{"name":"Rodrigo Fresco","is_ca":false},{"name":"Tetiana Taran","is_ca":false},{"name":"Arunava Chakravartty","is_ca":false},{"name":"Juan Pablo Zarate","is_ca":false},{"name":"Agnes Lteif","is_ca":false},{"name":"Gabriel N. Hortobágyi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0373529934834873,"gpt":0.3836976276393478,"spread":0.3463446341558605,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05800121,0.003357145,0.003894784,0.001853755,0.002583153,0.003267252,0.003411683,0.005822005,0.01785388],"category_scores_gemma":[0.04148613,0.002236635,0.002328791,0.001850667,0.004834429,0.002636118,0.001671823,0.007815777,0.007986967],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002501612,"about_ca_system_score_gemma":0.01003338,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008789632,"about_ca_topic_score_gemma":0.002598859,"domain_scores_codex":[0.9546955,0.03358844,0.002974551,0.003994824,0.003463443,0.001283242],"domain_scores_gemma":[0.9860729,0.0040328,0.002290313,0.001765833,0.002588658,0.003249435],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4644683,0.01217517,0.01318074,0.02352776,0.003882352,0.001896708,0.001669504,0.006055474,0.009857903,0.1028022,0.1472718,0.213212],"study_design_scores_gemma":[0.52255,0.04392109,0.01298686,0.01038778,0.003132429,0.001043893,0.000454838,0.01058373,0.003594934,0.04869352,0.3421746,0.0004762225],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.01051211,0.006296942,0.02217999,0.01112265,0.006684751,0.9250506,0.004355012,0.0003483212,0.01344972],"genre_scores_gemma":[0.02836167,0.001355903,0.02812693,0.01013178,0.001330624,0.9270746,0.001007671,0.00004518596,0.002565662],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.05800121,"threshold_uncertainty_score":0.3067434,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4391325299","doi":"10.1177/17588359231220511","title":"The role of aberrant DNA methylation in cancer initiation and clinical impacts","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Health and Medical Research Council; National Cancer Institute; National Institutes of Health; Sierra Oncology; Swiss Cancer Research Foundation; Eisai; BeiGene; Clovis Oncology; AstraZeneca","keywords":"DNA methylation; Epigenetics; Methylation; Cancer research; DNA repair; Biology; Cancer epigenetics; MSH2; Context (archaeology); MLH1; DNA mismatch repair; Medicine; Genetics; Gene; Gene expression","authors":[{"name":"Franziska Geissler","is_ca":false},{"name":"Ksenija Nesic","is_ca":false},{"name":"Olga Kondrashova","is_ca":false},{"name":"Alexander Dobrovic","is_ca":false},{"name":"Elizabeth M. Swisher","is_ca":false},{"name":"Clare L. Scott","is_ca":false},{"name":"Matthew J. Wakefield","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02222546235469653,"gpt":0.4208826697653826,"spread":0.3986572074106861,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007478601,0.0002577109,0.0005832827,0.0007739065,0.0002783702,0.001004589,0.0003125562,0.0007118213,0.001394696],"category_scores_gemma":[0.001160607,0.0001674353,0.000303677,0.0006704118,0.0008066857,0.000714189,0.0005713296,0.001122293,0.000457571],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008163564,"about_ca_system_score_gemma":0.0008041629,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001035328,"about_ca_topic_score_gemma":0.001073851,"domain_scores_codex":[0.9996454,0.0001045838,0.00003738038,0.00007650874,0.00009164427,0.00004452648],"domain_scores_gemma":[0.9995728,0.0002357201,0.00007455951,0.00001836469,0.00006828405,0.0000301925],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005300913,0.00007315013,0.02119835,0.009212147,0.0002673527,0.002930577,0.001162107,0.00301816,0.1003188,0.04766342,0.01107949,0.8025464],"study_design_scores_gemma":[0.00002704059,0.0006024005,0.06745246,0.003299422,0.0003785794,0.01508598,0.0008288056,0.001579757,0.06188428,0.04485445,0.8038666,0.00014019],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01727188,0.9659602,0.004688113,0.004040467,0.0004665978,0.00002008117,0.0002558696,0.0000552803,0.00724161],"genre_scores_gemma":[0.1385704,0.8538586,0.002754685,0.0008748315,0.0007082919,0.00003358363,0.0001866518,0.00001634908,0.002996595],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001394696,"threshold_uncertainty_score":0.005923152,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3195679999","doi":"10.1177/17588359211035959","title":"The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Molecular pathology; Subtyping; Medicine; Endometrial cancer; Molecular diagnostics; Targeted therapy; Bioinformatics; Molecular marker; Cancer; Oncology; Internal medicine; Computational biology; Pathology; Biology; Gene; Genetics; Computer science","authors":[{"name":"Amy Jamieson","is_ca":true},{"name":"Tjalling Bosse","is_ca":false},{"name":"Jessica N. McAlpine","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04628385487803262,"gpt":0.4449737521368726,"spread":0.39868989725884,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097957,0.0005124676,0.0009774519,0.001793763,0.0002338496,0.001126006,0.0006195989,0.0009914176,0.001963839],"category_scores_gemma":[0.001452332,0.0002086233,0.0005343742,0.001481691,0.0006291323,0.001362331,0.0006452648,0.00201794,0.0009079722],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006842884,"about_ca_system_score_gemma":0.001119176,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001247122,"about_ca_topic_score_gemma":0.002451973,"domain_scores_codex":[0.9997434,0.00008047808,0.00003448916,0.00003668609,0.00008228653,0.00002271236],"domain_scores_gemma":[0.9993774,0.0003990401,0.00005248499,0.00001516906,0.0001310925,0.00002483214],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005218787,0.00003886003,0.0002223653,0.01386552,0.00009191352,0.0001723316,0.00007454551,0.0004432733,0.001192861,0.006053108,0.01518291,0.9626101],"study_design_scores_gemma":[0.00002193281,0.0001258248,0.00133137,0.007444183,0.0001631398,0.001500756,0.0001035645,0.0002149916,0.0005245429,0.005005862,0.983538,0.00002596609],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00008745155,0.9986103,0.000125395,0.0004487328,0.0001296051,0.000002410087,0.000009038788,0.000003942786,0.000583083],"genre_scores_gemma":[0.0007823866,0.9983511,0.000224022,0.0003090835,0.0001401371,0.000004221577,0.0000136163,0.000001189691,0.0001742718],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001963839,"threshold_uncertainty_score":0.006569624,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3202940729","doi":"10.1177/17588359211047352","title":"Metastatic Urothelial Cancer: a rapidly changing treatment landscape","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Urothelial cancer; Immunotherapy; Clinical trial; Oncology; Chemotherapy; Disease; Cancer; Internal medicine; Intensive care medicine; Bladder cancer; Urothelial carcinoma","authors":[{"name":"Carlos Stecca","is_ca":true},{"name":"Osama Abdeljalil","is_ca":true},{"name":"Srikala S. Sridhar","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06794330522167166,"gpt":0.4500267465703506,"spread":0.382083441348679,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008154942,0.0005030205,0.00134391,0.001601981,0.0002704039,0.0010963,0.0006590076,0.0008818792,0.003320063],"category_scores_gemma":[0.001053323,0.0001776518,0.000551683,0.001895196,0.0003727036,0.001316632,0.0005769045,0.001725568,0.001336102],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006713626,"about_ca_system_score_gemma":0.001515135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009618166,"about_ca_topic_score_gemma":0.002676638,"domain_scores_codex":[0.9997162,0.00007333384,0.00004356612,0.00004096344,0.0001027049,0.00002305913],"domain_scores_gemma":[0.999426,0.0003099348,0.00006494097,0.00001295631,0.0001473622,0.00003887982],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006457269,0.0000492327,0.0001888474,0.02692866,0.0001010132,0.0001724104,0.00006404965,0.0003201298,0.00110445,0.003860871,0.0311027,0.9360429],"study_design_scores_gemma":[0.00001979562,0.0001202711,0.0008013025,0.008121452,0.0001731288,0.001156626,0.00008246883,0.00009283202,0.0002379189,0.002140764,0.9870362,0.00001727629],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009827626,0.9983886,0.00007695254,0.0006499646,0.0001639628,0.0000028998,0.00001881268,0.000006057538,0.0005944901],"genre_scores_gemma":[0.0004364149,0.9988181,0.000100566,0.0003201745,0.0001266981,0.000003056306,0.00002410641,0.000001125365,0.0001698019],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003320063,"threshold_uncertainty_score":0.01110673,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2945349403","doi":"10.1177/1758835919850367","title":"Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine <i>versus</i> FOLFIRINOX in advanced pancreatic cancer: a systematic review","year":2019,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Alberta Health Services","funders":"Celgene","keywords":"FOLFIRINOX; Medicine; Gemcitabine; Irinotecan; Internal medicine; Oxaliplatin; Neutropenia; Oncology; Pancreatic cancer; Gastroenterology; Cancer; Chemotherapy; Colorectal cancer","authors":[{"name":"E. Gabriela Chiorean","is_ca":false},{"name":"Winson Y. Cheung","is_ca":true},{"name":"Guido Giordano","is_ca":false},{"name":"George Kim","is_ca":false},{"name":"Salah‐Eddin Al‐Batran","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1137865024179143,"gpt":0.5148520294269145,"spread":0.4010655270090003,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01426696,0.001409133,0.01205467,0.009164308,0.0006278528,0.003276662,0.001861783,0.001964331,0.003141375],"category_scores_gemma":[0.04192007,0.001150698,0.01025196,0.007999417,0.001157991,0.002234119,0.001371574,0.001127907,0.0002415658],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004369635,"about_ca_system_score_gemma":0.009567787,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005401736,"about_ca_topic_score_gemma":0.01704437,"domain_scores_codex":[0.9853314,0.006233406,0.005637722,0.0009156254,0.001590331,0.0002915497],"domain_scores_gemma":[0.9573556,0.02907362,0.009405251,0.0006425955,0.003030742,0.0004922958],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0007279234,0.0000197724,0.0008622037,0.9508228,0.03473044,0.00008476364,0.0001489136,0.00008068496,0.0002110082,0.00009942911,0.000362087,0.01184997],"study_design_scores_gemma":[0.001653826,0.0009031114,0.005633019,0.6579472,0.3240675,0.0003959038,0.0004102868,0.0001666445,0.0003344489,0.000270104,0.008161115,0.00005683988],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00515318,0.9926553,0.0002018873,0.0002565286,0.0001275721,0.0007944505,0.0004968122,0.00001208018,0.0003022049],"genre_scores_gemma":[0.09055014,0.903946,0.001695306,0.001046716,0.0001805622,0.001851741,0.0005171848,0.00001513279,0.0001971783],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01426696,"threshold_uncertainty_score":0.07545173,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3001249325","doi":"10.1177/1758835919895756","title":"Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Anaplastic lymphoma kinase; Cancer research; ROS1; Epidermal growth factor receptor; Medicine; Mutation; Lung cancer; Anaplastic large-cell lymphoma; PI3K/AKT/mTOR pathway; ERBB3; Fusion gene; Protein kinase domain; Cancer; Lymphoma; Biology; Gene; Oncology; Signal transduction; Adenocarcinoma; Genetics; Immunology; Internal medicine","authors":[{"name":"Quincy S. Chu","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01754185532272969,"gpt":0.3809251556186141,"spread":0.3633833002958844,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002008147,0.0004781571,0.00076146,0.00137897,0.0001527814,0.0005723434,0.000391879,0.0004999807,0.004039764],"category_scores_gemma":[0.0002764147,0.0001370365,0.0003883185,0.001113694,0.0001419591,0.0006488637,0.0003918973,0.0009894525,0.001993639],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002815709,"about_ca_system_score_gemma":0.0004811144,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004478229,"about_ca_topic_score_gemma":0.001116578,"domain_scores_codex":[0.9999304,0.00001085957,0.000009543379,0.00001307524,0.00002701799,0.000009127222],"domain_scores_gemma":[0.99992,0.00003559565,0.00001329371,0.000002368713,0.00002068613,0.000007874299],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000736749,0.00007447186,0.0001145149,0.01811586,0.00009372338,0.0002375976,0.00004795553,0.0003005929,0.003500888,0.002880948,0.03126325,0.9432966],"study_design_scores_gemma":[0.00001734066,0.0001101064,0.000470207,0.002560035,0.0001215866,0.001419477,0.00003104502,0.00007592481,0.0005846129,0.00102425,0.9935753,0.00001006485],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002624527,0.9970469,0.0001504604,0.0002162256,0.0001873625,0.00000773274,0.00004109156,0.00001055038,0.002077204],"genre_scores_gemma":[0.0009760329,0.9974644,0.0001690977,0.0002000431,0.00008898941,0.000008202956,0.00006080177,0.000001965292,0.001030447],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004039764,"threshold_uncertainty_score":0.01351434,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4288013778","doi":"10.1177/17588359221112696","title":"The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Niagara Health System; University of Toronto; Princess Margaret Cancer Centre; Ottawa Hospital; University of British Columbia; University of Ottawa; Jewish General Hospital; McMaster University; Juravinski Cancer Centre; McGill University; University of Calgary","funders":"Jewish General Hospital; BC Cancer Foundation; Princess Margaret Cancer Foundation; Guardant Health; Ottawa Hospital Research Institute","keywords":"Liquid biopsy; Medicine; Lung cancer; Biopsy; Circulating tumor DNA; Cell-free fetal DNA; Lung; Oncology; Pathology; Cancer research; Internal medicine; Cancer; Biology; Genetics","authors":[{"name":"Doreen A. Ezeife","is_ca":true},{"name":"Eldon Spackman","is_ca":true},{"name":"Rosalyn A. Juergens","is_ca":true},{"name":"Janessa Laskin","is_ca":true},{"name":"Jason Agulnik","is_ca":true},{"name":"Desirée Hao","is_ca":true},{"name":"Scott A. Laurie","is_ca":true},{"name":"Jennifer Law","is_ca":true},{"name":"Lisa W. Le","is_ca":true},{"name":"Lesli A. Kiedrowski","is_ca":false},{"name":"Barbara Melosky","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Victor Cohen","is_ca":true},{"name":"Paul Wheatley‐Price","is_ca":true},{"name":"R Vandermeer","is_ca":true},{"name":"Janice J.N. Li","is_ca":true},{"name":"Roxanne Fernandes","is_ca":true},{"name":"Aria Shokoohi","is_ca":true},{"name":"Richard B. Lanman","is_ca":false},{"name":"Natasha B. Leighl","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.008545333577232495,"gpt":0.3190650196068914,"spread":0.310519686029659,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005159981,0.0008273398,0.0007052506,0.0009610224,0.0004312794,0.001642179,0.00100333,0.0007294008,0.00238319],"category_scores_gemma":[0.01677204,0.0003903085,0.001663075,0.001165691,0.000843811,0.0008573687,0.000839882,0.001102128,0.0000944619],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02621689,"about_ca_system_score_gemma":0.01553991,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.3311591,"about_ca_topic_score_gemma":0.2756794,"domain_scores_codex":[0.9968281,0.002080468,0.0000875456,0.0001620601,0.000462542,0.0003792748],"domain_scores_gemma":[0.9900231,0.008152717,0.0007682939,0.0001314841,0.0004871302,0.0004372973],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","study_design_scores_codex":[0.009482658,0.0003635363,0.05231441,0.001175515,0.001428611,0.0002813934,0.0000916536,0.855098,0.0009858119,0.006352,0.00269998,0.06972642],"study_design_scores_gemma":[0.001862099,0.003582963,0.06469914,0.0009282799,0.002808821,0.0004843433,0.0003263352,0.9090299,0.001366446,0.009211031,0.005552039,0.0001485146],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9498012,0.01113665,0.0144242,0.005049886,0.00009778681,0.001205072,0.004948329,0.00008948384,0.0132474],"genre_scores_gemma":[0.9962348,0.0008628556,0.001998217,0.0001438497,0.00001034781,0.0000588763,0.000436085,0.000004357391,0.0002506225],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3311591,"threshold_uncertainty_score":0.6584631,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2787639107","doi":"10.1177/1758834017753338","title":"Turning <i>EGFR</i> mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors","year":2018,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Osimertinib; Afatinib; Erlotinib; T790M; Gefitinib; Medicine; Lung cancer; Tolerability; Oncology; Epidermal growth factor receptor; Resistance mutation; Erlotinib Hydrochloride; Tyrosine kinase; Internal medicine; Cancer research; Cancer; Adverse effect; Biology; Receptor","authors":[{"name":"Vera Hirsh","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0187632283556493,"gpt":0.4154327985471971,"spread":0.3966695701915478,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004114092,0.0002429827,0.0005025596,0.0001631614,0.0001738086,0.0007772097,0.0002794778,0.0003937116,0.0007779948],"category_scores_gemma":[0.0005290045,0.0001177685,0.000286987,0.0001161311,0.0002676979,0.0008291324,0.0004123446,0.001079114,0.0003279734],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003872505,"about_ca_system_score_gemma":0.0006786974,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003033844,"about_ca_topic_score_gemma":0.001424999,"domain_scores_codex":[0.9998403,0.00004492806,0.00002218689,0.00002068707,0.00003696813,0.00003492893],"domain_scores_gemma":[0.9998535,0.00003939934,0.00004035598,0.000005858401,0.00002017864,0.0000406919],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001665438,0.0006959683,0.00491534,0.00203071,0.0001398424,0.001597681,0.0002056837,0.002988934,0.04911826,0.008296377,0.01794818,0.9103976],"study_design_scores_gemma":[0.002000213,0.01834673,0.05220787,0.00431499,0.0009307414,0.03085732,0.001474028,0.02128947,0.05013701,0.03702007,0.7812153,0.0002062735],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.2159303,0.6864761,0.03537372,0.026656,0.002459982,0.000303764,0.00015824,0.0003630891,0.03227882],"genre_scores_gemma":[0.6956035,0.2680036,0.02281003,0.004840821,0.003530102,0.0001864738,0.0002786558,0.00006036336,0.004686487],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.0007779948,"threshold_uncertainty_score":0.002809703,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3191554850","doi":"10.1177/17588359211036544","title":"IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Bevacizumab; Gemcitabine; Clinical endpoint; Oncology; Chemotherapy; Internal medicine; Tumor microenvironment; Cancer; Immunotherapy; Clinical trial; Nivolumab","authors":[{"name":"Stephen P. Hack","is_ca":false},{"name":"Wendy Verret","is_ca":false},{"name":"Sohail Mulla","is_ca":true},{"name":"Bo Liu","is_ca":false},{"name":"Yulei Wang","is_ca":false},{"name":"Teresa Macarulla","is_ca":false},{"name":"Zhenggang Ren","is_ca":false},{"name":"Anthony B. El-Khoueiry","is_ca":false},{"name":"Andrew X. Zhu","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01165188480779092,"gpt":0.3378004446659155,"spread":0.3261485598581245,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002436336,0.00212142,0.003065175,0.0005486424,0.0004301202,0.001580283,0.001383435,0.002147431,0.006543014],"category_scores_gemma":[0.001805133,0.001021407,0.002011464,0.0004242197,0.001488774,0.001582963,0.0006365224,0.003547482,0.001477927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001082897,"about_ca_system_score_gemma":0.001466801,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007665218,"about_ca_topic_score_gemma":0.00173236,"domain_scores_codex":[0.9991652,0.0004699127,0.00004430403,0.0001499867,0.00004751039,0.0001230854],"domain_scores_gemma":[0.9988291,0.0002109523,0.0002427655,0.0001020398,0.00006821458,0.0005469184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.970453,0.01062504,0.0009362287,0.0004371131,0.000679648,0.00003670267,0.00004745902,0.0003943845,0.003796405,0.0001356135,0.0009852177,0.01147327],"study_design_scores_gemma":[0.9011625,0.09551803,0.001449541,0.00002084545,0.0003083042,0.00004302763,0.00001929666,0.0004103572,0.0003199599,0.00008730951,0.0006451154,0.00001573598],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850925,0.003587869,0.0005412904,0.001098055,0.0007221345,0.004654336,0.001152459,0.0001829793,0.002968434],"genre_scores_gemma":[0.9809124,0.001960466,0.001889592,0.002264721,0.0006242116,0.005762038,0.002669657,0.00004236648,0.003874636],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006543014,"threshold_uncertainty_score":0.02188855,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2610105293","doi":"10.1177/1758834017704329","title":"Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice","year":2017,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical Practice; Affect (linguistics); Lung cancer; Medical physics; Oncology; Intensive care medicine; Family medicine; Psychology","authors":[{"name":"Petra Martin","is_ca":true},{"name":"Natasha B. Leighl","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.317195944797893,"gpt":0.5822947835792166,"spread":0.2650988387813236,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009945409,0.0006567755,0.001227053,0.003508535,0.0002527637,0.0008883541,0.000820876,0.0009488594,0.004181871],"category_scores_gemma":[0.003557587,0.0002872361,0.0009563882,0.002837942,0.0003995853,0.00117784,0.0004835095,0.001325487,0.001237861],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007513766,"about_ca_system_score_gemma":0.001796418,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001815005,"about_ca_topic_score_gemma":0.003130044,"domain_scores_codex":[0.9995127,0.0001223403,0.0001245566,0.00006526911,0.0001522601,0.00002290578],"domain_scores_gemma":[0.9982647,0.00115248,0.0002250562,0.00002589093,0.0002836811,0.00004824287],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.00007180168,0.00004733218,0.0004359332,0.0562241,0.0002518589,0.000235494,0.0001020311,0.0004049345,0.0004859916,0.002927809,0.05227977,0.8865328],"study_design_scores_gemma":[0.00002314613,0.00009835684,0.002152334,0.03507784,0.0005302848,0.002312546,0.00008978196,0.0001305751,0.0002551732,0.002298015,0.9569975,0.00003453298],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007611517,0.9983783,0.0001058663,0.0004751318,0.0001997138,0.000006471893,0.00004221267,0.000005545199,0.0007106527],"genre_scores_gemma":[0.0005231223,0.9984842,0.0002135338,0.0003228517,0.0001846924,0.000008334769,0.00004005843,0.000001609733,0.000221596],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004181871,"threshold_uncertainty_score":0.01398975,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3172779990","doi":"10.1177/17588359211019675","title":"Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Regional Municipality of Durham; Lakeridge Health; Queen's University; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Karl Landsteiner Privatuniversität für Gesundheitswissenschaften","keywords":"Medicine; Internal medicine; Brain metastasis; Lung cancer; Oncology; Adverse effect; Retrospective cohort study; Confidence interval; Population; Fusion gene; Cancer; Metastasis; Gene","authors":[{"name":"Oliver Illini","is_ca":false},{"name":"Maximilian J. Hochmair","is_ca":false},{"name":"Hannah Fabikan","is_ca":false},{"name":"Christoph Weinlinger","is_ca":false},{"name":"Amanda Tufman","is_ca":false},{"name":"Aurélie Swalduz","is_ca":false},{"name":"Kristina Lamberg","is_ca":false},{"name":"Sayed M.S. Hashemi","is_ca":false},{"name":"Florian Huemer","is_ca":false},{"name":"Anders Vikström","is_ca":false},{"name":"Martin Wermke","is_ca":false},{"name":"Gudrun Absenger","is_ca":false},{"name":"Alfredo Addeo","is_ca":false},{"name":"Shantanu Banerji","is_ca":true},{"name":"Antonio Calles","is_ca":false},{"name":"Stephen Clarke","is_ca":false},{"name":"Massimo Di Maïo","is_ca":false},{"name":"Alice Durand","is_ca":false},{"name":"M. Duruisseaux","is_ca":false},{"name":"Malinda Itchins","is_ca":false},{"name":"Okko-Sakari Kääränien","is_ca":false},{"name":"Florian Krenn","is_ca":false},{"name":"Eckart Laack","is_ca":false},{"name":"Adrianus J. de Langen","is_ca":false},{"name":"Katja Mohorčič","is_ca":false},{"name":"Georg Pall","is_ca":false},{"name":"Antonio Passaro","is_ca":false},{"name":"G. Prager","is_ca":false},{"name":"Achim Rittmeyer","is_ca":false},{"name":"J. Rothenstein","is_ca":true},{"name":"Michael A. Schumacher","is_ca":false},{"name":"Ewald Wöll","is_ca":false},{"name":"Arschang Valipour","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01930944574526549,"gpt":0.4443961404085657,"spread":0.4250866946633002,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000864635,0.0002158308,0.0004477352,0.0008172177,0.0003489018,0.0006388723,0.0002581619,0.0003529655,0.001034962],"category_scores_gemma":[0.001229222,0.0002693325,0.0005500669,0.0009849089,0.0003156439,0.0004488608,0.0004946525,0.000326631,0.0002319092],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003150837,"about_ca_system_score_gemma":0.0003280734,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001478229,"about_ca_topic_score_gemma":0.001663427,"domain_scores_codex":[0.9992115,0.0001832582,0.0001311428,0.0002318594,0.0001509537,0.0000912439],"domain_scores_gemma":[0.9985429,0.0003372049,0.0006932245,0.0001219281,0.0001333461,0.0001713661],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005152251,0.00005726366,0.996987,0.00001740482,0.00009365012,0.0002870568,0.00005922017,0.00006182455,0.000316633,0.00001553681,0.00008243144,0.001506716],"study_design_scores_gemma":[0.00004690039,0.0007415898,0.9963141,0.00001167591,0.0001118022,0.001576852,0.0001900892,0.0002686133,0.0002440212,0.00001791865,0.0004690855,0.000007322307],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9991924,0.0002507414,0.00005028894,0.000009415612,0.000001749443,0.00001383103,0.0002748613,0.000001943839,0.0002046269],"genre_scores_gemma":[0.9992328,0.0001231673,0.00003082322,0.00002214957,0.000005307008,0.00001195507,0.0005113051,0.000001472342,0.00006101561],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001478229,"threshold_uncertainty_score":0.00457269,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2156077273","doi":"10.1177/1758834009358417","title":"Renal cell carcinoma bone metastases: clinical advances","year":2010,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Zoledronic acid; Oncology; Systemic therapy; Targeted therapy; Bone disease; Clinical trial; Kidney cancer; Internal medicine; Cancer; Breast cancer; Osteoporosis","authors":[{"name":"Chakshu Sahi","is_ca":true},{"name":"Jennifer J. Knox","is_ca":true},{"name":"Mark Clemons","is_ca":true},{"name":"Anthony M. Joshua","is_ca":true},{"name":"Reuben Broom","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04202467694925865,"gpt":0.4341992174272958,"spread":0.3921745404780371,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002010151,0.0003865598,0.0006115338,0.0007734096,0.0002158492,0.001196094,0.0004997306,0.0008121417,0.002265889],"category_scores_gemma":[0.002072432,0.0001315541,0.0004165952,0.00119232,0.00053954,0.001086996,0.000411408,0.001200054,0.0007930329],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005864528,"about_ca_system_score_gemma":0.001378546,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000895768,"about_ca_topic_score_gemma":0.002294539,"domain_scores_codex":[0.999626,0.00008051837,0.00005033409,0.00005164186,0.000155785,0.00003579164],"domain_scores_gemma":[0.9987435,0.0005357907,0.0001519472,0.00006338259,0.0003671525,0.0001382784],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002988914,0.0001826536,0.002868874,0.002089228,0.00005403733,0.0005011582,0.00007357379,0.0003181088,0.002662645,0.00266031,0.01083405,0.9774564],"study_design_scores_gemma":[0.0003289003,0.003084838,0.02044583,0.00307982,0.0004104211,0.01024179,0.0002681054,0.001146674,0.007071066,0.005277128,0.9485863,0.00005909513],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.006891788,0.9747328,0.001256035,0.006701741,0.0005802349,0.00004274636,0.0001037789,0.00004820383,0.009642751],"genre_scores_gemma":[0.07631319,0.9105529,0.003859312,0.003585418,0.002839908,0.00003960528,0.0003196676,0.00001652105,0.002473491],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002265889,"threshold_uncertainty_score":0.01063085,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3199693232","doi":"10.1177/17588359211034708","title":"New approaches to first-line treatment of advanced renal cell carcinoma","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Exelixis","keywords":"Axitinib; Medicine; Nivolumab; Pazopanib; Pembrolizumab; Cabozantinib; Sunitinib; Ipilimumab; Renal cell carcinoma; Oncology; Tyrosine-kinase inhibitor; Internal medicine; Avelumab; Kidney cancer; Lenvatinib; Immunotherapy; Cancer","authors":[{"name":"Daniel J. George","is_ca":false},{"name":"Chung‐Han Lee","is_ca":false},{"name":"Daniel Y.C. Heng","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1690109399906946,"gpt":0.3992702987299874,"spread":0.2302593587392927,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005002402,0.0007096069,0.001083295,0.002062432,0.0002261222,0.0007619043,0.0006743958,0.0006299629,0.003784842],"category_scores_gemma":[0.0004739227,0.0002110949,0.0006348556,0.001438191,0.0003135758,0.001010491,0.0005073649,0.002083112,0.001825472],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005692556,"about_ca_system_score_gemma":0.0008394324,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000827831,"about_ca_topic_score_gemma":0.00227743,"domain_scores_codex":[0.999811,0.00003594746,0.00002718925,0.00003303733,0.00007761941,0.00001529785],"domain_scores_gemma":[0.9998248,0.00008105618,0.00002835512,0.000005620542,0.00004610829,0.00001406258],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000752878,0.00008527777,0.0001051051,0.02107804,0.0001167101,0.0001307733,0.00004368354,0.0003210765,0.001541539,0.003782235,0.02731099,0.9454093],"study_design_scores_gemma":[0.00003418083,0.0001254353,0.0005877698,0.0040369,0.0001343065,0.0008775824,0.00003009919,0.00009681064,0.0003505071,0.001538959,0.992173,0.00001462389],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00008084555,0.9985304,0.000114069,0.0001957815,0.0001702311,0.000005759306,0.00001725948,0.000007385334,0.0008782265],"genre_scores_gemma":[0.0004052737,0.9987283,0.0001651213,0.0001837032,0.0001228815,0.000006101398,0.00003031976,0.000001245038,0.0003571353],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003784842,"threshold_uncertainty_score":0.01266152,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4285189908","doi":"10.1177/17588359221108685","title":"Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Calgary; Queen Elizabeth II Health Sciences Centre; McMaster University; Juravinski Cancer Centre","funders":"Pfizer Canada; Merck Canada; Ipsen; Eisai","keywords":"Medicine; Cancer therapy; Systematic review; Cancer; Kidney cancer; Oncology; MEDLINE; Intensive care medicine; Internal medicine","authors":[{"name":"Aly‐Khan A. Lalani","is_ca":true},{"name":"Daniel Y.C. Heng","is_ca":true},{"name":"Naveen S. Basappa","is_ca":false},{"name":"Lori Wood","is_ca":true},{"name":"Nayyer Iqbal","is_ca":false},{"name":"Deanna McLeod","is_ca":false},{"name":"Denis Soulières","is_ca":true},{"name":"Christian Kollmannsberger","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06161452145770124,"gpt":0.4158854827627571,"spread":0.3542709613050559,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006732265,0.000825335,0.007408303,0.006150601,0.0003282026,0.001887731,0.00146237,0.001250671,0.003295519],"category_scores_gemma":[0.02972399,0.0007006951,0.005935415,0.008033427,0.0005705286,0.001921915,0.0008706735,0.001047098,0.0002203749],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002815664,"about_ca_system_score_gemma":0.006745517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007147339,"about_ca_topic_score_gemma":0.02327484,"domain_scores_codex":[0.9943474,0.002366183,0.001894911,0.000437387,0.0008280274,0.0001261563],"domain_scores_gemma":[0.9668105,0.02369442,0.006556394,0.0003088198,0.00233245,0.0002973541],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0003956461,0.00001949456,0.001121855,0.9170836,0.01535351,0.00007840677,0.0001177163,0.0001497732,0.0001049544,0.0002445512,0.002089004,0.06324152],"study_design_scores_gemma":[0.0006432689,0.0004458224,0.007204424,0.8546382,0.1057458,0.0006051221,0.0002352489,0.0002061622,0.0001311354,0.0004046389,0.02968857,0.00005152537],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005009098,0.9989095,0.0000475155,0.0001611287,0.00004102331,0.00004756365,0.0001610729,0.00000268138,0.0001286998],"genre_scores_gemma":[0.01232151,0.9864916,0.0003160912,0.0004482169,0.00006625814,0.0001362239,0.0001720465,0.000003244581,0.0000447916],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007408303,"threshold_uncertainty_score":0.03560406,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3011081636","doi":"10.1177/1758835920911229","title":"Widespread expression of Sonic hedgehog (Shh) and Nrf2 in patients treated with cisplatin predicts outcome in resected tumors and are potential therapeutic targets for HPV-negative head and neck cancer","year":2020,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children; McGill University","funders":"","keywords":"Sonic hedgehog; Medicine; Cyclopamine; Cancer research; Clonogenic assay; Hedgehog; Cisplatin; Context (archaeology); Vismodegib; Cancer; Oncology; Head and neck squamous-cell carcinoma; Hedgehog signaling pathway; Head and neck cancer; Internal medicine; Chemotherapy; Cell; Biology; Signal transduction; Basal cell carcinoma","authors":[{"name":"Abu Shadat Mohammod Noman","is_ca":true},{"name":"Rashed R. Parag","is_ca":false},{"name":"Muhammad Rashid","is_ca":false},{"name":"Mohammad Zeshaan Rahman","is_ca":false},{"name":"Afrin Sultana","is_ca":false},{"name":"Chandsultana Jerin","is_ca":false},{"name":"Ayesha Siddiqua","is_ca":false},{"name":"Lutfur Rahman","is_ca":false},{"name":"Afsana Shirin","is_ca":false},{"name":"Junayed Nayeem","is_ca":false},{"name":"Reaz Mahmud","is_ca":false},{"name":"Sonam Akther","is_ca":false},{"name":"Rajib Shil","is_ca":false},{"name":"Ikram Hossain","is_ca":false},{"name":"Arfina Chowdhury","is_ca":false},{"name":"Shabnam B. Basher","is_ca":false},{"name":"Abul Hasan","is_ca":false},{"name":"Shammy Bithy","is_ca":false},{"name":"Jannatul Aklima","is_ca":false},{"name":"Mizanur Rahman","is_ca":false},{"name":"Nabila Chowdhury","is_ca":false},{"name":"Tahmina Banu","is_ca":false},{"name":"Bedri Karakas","is_ca":false},{"name":"Herman Yeger","is_ca":true},{"name":"Walid A. Farhat","is_ca":false},{"name":"Syed S. Islam","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02253777044378503,"gpt":0.3312867025453674,"spread":0.3087489321015823,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002118967,0.0001258807,0.0002211073,0.0004006124,0.0001806217,0.0002398732,0.0001662469,0.000219656,0.001528984],"category_scores_gemma":[0.0006124828,0.00007993769,0.0002456658,0.0003337083,0.0001638464,0.0001933025,0.0003051694,0.0002404225,0.0001644948],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001942398,"about_ca_system_score_gemma":0.0002204676,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008597489,"about_ca_topic_score_gemma":0.001737673,"domain_scores_codex":[0.9998925,0.00001456041,0.00001625168,0.00003420104,0.00002278798,0.00001974542],"domain_scores_gemma":[0.9996936,0.00005782163,0.0001230778,0.00001969087,0.00003972518,0.00006607715],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004836046,0.00002615396,0.9897684,0.00002964735,0.00005177952,0.00009968149,0.00002044856,0.0001184733,0.005443255,0.00001719882,0.0001382542,0.003803126],"study_design_scores_gemma":[0.000007769907,0.0001257645,0.9974274,0.000006162232,0.00006074074,0.00038488,0.00005605838,0.0003265433,0.001134723,0.00005127709,0.0004163437,0.000002347183],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9985065,0.0004302071,0.0001958138,0.00003802421,0.000004354111,0.000009460292,0.0004619643,0.000006985094,0.0003466218],"genre_scores_gemma":[0.9990867,0.0001057053,0.0001107872,0.00001119546,0.000003797825,0.000007709582,0.0005148599,0.000001648266,0.000157546],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001528984,"threshold_uncertainty_score":0.005114913,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3009738710","doi":"10.1177/1758835920915299","title":"Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Servier; Ipsen Fund; NuCana","keywords":"Medicine; Internal medicine; Everolimus; Progression-free survival; Oncology; Prospective cohort study; Sample size determination; Chemotherapy","authors":[{"name":"Mairéad G. McNamara","is_ca":false},{"name":"Melissa Frizziero","is_ca":false},{"name":"Timothy W. Jacobs","is_ca":false},{"name":"Ángela Lamarca","is_ca":false},{"name":"Richard Hubner","is_ca":false},{"name":"Juan W. Valle","is_ca":false},{"name":"Eitan Amir","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05922102353235283,"gpt":0.4006608372262131,"spread":0.3414398136938603,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007185731,0.001776294,0.01359762,0.005539886,0.000395131,0.002207722,0.001701205,0.001488387,0.003049937],"category_scores_gemma":[0.01460713,0.0009301304,0.025161,0.006632729,0.0004535411,0.001316525,0.0009980163,0.001162326,0.0002606617],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00165445,"about_ca_system_score_gemma":0.002182524,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004457171,"about_ca_topic_score_gemma":0.01227076,"domain_scores_codex":[0.9956763,0.001850955,0.001372153,0.0005168212,0.0004415429,0.0001422994],"domain_scores_gemma":[0.9888171,0.007661668,0.00223869,0.000286386,0.0008014314,0.0001947621],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.00180932,0.00003275483,0.004565212,0.4629341,0.5163674,0.000158888,0.00007786489,0.0004586195,0.00028384,0.00009567612,0.0006436026,0.01257277],"study_design_scores_gemma":[0.0004930898,0.0002802014,0.005422866,0.03602891,0.9548115,0.0001753574,0.00005657507,0.0001649069,0.0001146673,0.0001450854,0.002281338,0.00002543718],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003610865,0.9953179,0.0002279937,0.000116883,0.00006697725,0.0001068097,0.0003905864,0.00001076689,0.0001512609],"genre_scores_gemma":[0.1462505,0.8500857,0.001168245,0.0007027165,0.0001676238,0.0004956358,0.0008913184,0.00001970902,0.000218576],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01359762,"threshold_uncertainty_score":0.03800219,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4205813526","doi":"10.1177/17588359211066677","title":"Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital; University of Calgary; Université Laval; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Toronto; Dalhousie University; University of British Columbia; BC Cancer Agency","funders":"F. Hoffmann-La Roche; AstraZeneca; Mylan; Pfizer","keywords":"Medicine; Trastuzumab; Neratinib; Oncology; Capecitabine; Internal medicine; Breast cancer; Hazard ratio; Clinical trial; Metastatic breast cancer; Cancer; Progression-free survival; Overall survival; Confidence interval; Colorectal cancer","authors":[{"name":"Christine Simmons","is_ca":true},{"name":"Daniel Rayson","is_ca":true},{"name":"Anil A. Joy","is_ca":true},{"name":"Jan‐Willem Henning","is_ca":true},{"name":"Julie Lemieux","is_ca":true},{"name":"Heather L. McArthur","is_ca":false},{"name":"Paul Card","is_ca":false},{"name":"Rebecca Dent","is_ca":false},{"name":"Christine Brezden‐Masley","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05377138215085864,"gpt":0.4747381370782596,"spread":0.420966754927401,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01416878,0.000688975,0.002517689,0.002578683,0.0004301481,0.004052018,0.001793608,0.002682287,0.006343753],"category_scores_gemma":[0.01234088,0.0003481357,0.00161824,0.003493841,0.001605727,0.008631899,0.001183914,0.002778366,0.001318289],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002701708,"about_ca_system_score_gemma":0.00548165,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001846644,"about_ca_topic_score_gemma":0.004933643,"domain_scores_codex":[0.9962279,0.001969558,0.0006444554,0.0003384766,0.0006376602,0.0001820164],"domain_scores_gemma":[0.981898,0.01172489,0.002711343,0.0003950382,0.002646659,0.0006240165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001253961,0.0001876102,0.002296852,0.03181102,0.0004077803,0.0002449536,0.0003134115,0.0007006039,0.001774346,0.01060444,0.0264985,0.9239065],"study_design_scores_gemma":[0.0008238081,0.002384123,0.009347972,0.1077037,0.002546017,0.002148172,0.002174199,0.00210026,0.001109591,0.03761673,0.831893,0.0001524185],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001089607,0.9770325,0.0004462257,0.02020938,0.0003576458,0.00001422488,0.00005514418,0.00002195143,0.0007733474],"genre_scores_gemma":[0.01496889,0.9673589,0.001917104,0.01322636,0.001717507,0.00005474023,0.0001279802,0.00002414723,0.0006042157],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01416878,"threshold_uncertainty_score":0.07493252,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4323024632","doi":"10.1177/17588359231157644","title":"Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; PARP inhibitor; Ovarian cancer; Oncology; Cancer research; Poly ADP ribose polymerase; Internal medicine; Cancer; Pharmacology; DNA; Biology; Genetics","authors":[{"name":"Ana Veneziani","is_ca":true},{"name":"Clare L. Scott","is_ca":false},{"name":"Matthew J. Wakefield","is_ca":false},{"name":"Anna V. Tinker","is_ca":true},{"name":"Stéphanie Lheureux","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09070451031767579,"gpt":0.4848637584573334,"spread":0.3941592481396576,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003493305,0.0004320786,0.0007898216,0.001170547,0.0001963722,0.0007301109,0.0005311491,0.0006381758,0.003054215],"category_scores_gemma":[0.0003918772,0.0001517684,0.000427413,0.0009389422,0.0002263582,0.0008472512,0.0004758475,0.001459238,0.001347387],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004004507,"about_ca_system_score_gemma":0.0005698851,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004823697,"about_ca_topic_score_gemma":0.001358425,"domain_scores_codex":[0.9998761,0.00002594615,0.00001586218,0.00002086714,0.00004670379,0.00001443709],"domain_scores_gemma":[0.9998813,0.00004901355,0.00002060669,0.000003559113,0.00003379093,0.00001184008],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000934299,0.00009048751,0.000153136,0.01493988,0.00007612963,0.000232423,0.00006819603,0.0003818589,0.00288152,0.003315002,0.01785013,0.9599178],"study_design_scores_gemma":[0.0000314516,0.0002609948,0.0008305368,0.00359923,0.0001178973,0.001577571,0.000068544,0.0001678725,0.001161373,0.001996037,0.9901714,0.00001714147],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003162355,0.9975859,0.0002135883,0.0004139782,0.0001680072,0.000009842381,0.00002779754,0.00001053539,0.001254074],"genre_scores_gemma":[0.001538505,0.9969953,0.0002647122,0.0002791999,0.0001177285,0.00001024388,0.00005197452,0.000001926704,0.0007404296],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003054215,"threshold_uncertainty_score":0.01021731,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2945903793","doi":"10.1177/1758835919846372","title":"FAM84B promotes prostate tumorigenesis through a network alteration","year":2019,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"Cancer Research Society","keywords":"DU145; Cancer research; Carcinogenesis; Prostate cancer; Cell growth; Biology; Metastasis; Cell cycle; Cell; Cancer; Medicine; Genetics; LNCaP","authors":[{"name":"Yanzhi Jiang","is_ca":true},{"name":"Xiaozeng Lin","is_ca":true},{"name":"Anil Kapoor","is_ca":true},{"name":"Lizhi He","is_ca":false},{"name":"Fengxiang Wei","is_ca":false},{"name":"Yan Gu","is_ca":true},{"name":"Wenjuan Mei","is_ca":true},{"name":"Kuncheng Zhao","is_ca":true},{"name":"Huixiang Yang","is_ca":false},{"name":"Damu Tang","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02679852681546533,"gpt":0.3997595675188897,"spread":0.3729610407034244,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008500853,0.000366957,0.0002232762,0.0003713865,0.0002410691,0.0003625159,0.0001435777,0.0002431895,0.002132581],"category_scores_gemma":[0.0001023409,0.0001342754,0.0004016897,0.0003895754,0.0001505174,0.0002365484,0.000340273,0.0002627186,0.0003655932],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004077251,"about_ca_system_score_gemma":0.0002578318,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008216971,"about_ca_topic_score_gemma":0.0008413518,"domain_scores_codex":[0.9998795,0.00001445681,0.000005381127,0.0000417351,0.00002636597,0.00003259534],"domain_scores_gemma":[0.9998832,0.000009768394,0.00005843612,0.000007907096,0.00001589255,0.00002493096],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0005086137,0.00005311643,0.01182221,0.0002525522,0.0001156312,0.0002566446,0.00003235468,0.0008035881,0.9768472,0.0003741282,0.0003748121,0.008559068],"study_design_scores_gemma":[0.00008279976,0.001164331,0.5217741,0.00009111084,0.000552402,0.002376371,0.0003279907,0.01918007,0.429065,0.0016036,0.02373579,0.00004647809],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886639,0.003596637,0.003886847,0.0001864855,0.00002425946,0.00002367323,0.001836175,0.000198865,0.001583139],"genre_scores_gemma":[0.9934308,0.001553351,0.001840272,0.0000665744,0.000008905312,0.00002593726,0.001651077,0.00001629114,0.001406891],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002132581,"threshold_uncertainty_score":0.007134259,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3139304883","doi":"10.1177/1758835921998586","title":"Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"Myovant Sciences","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Adverse effect; Testosterone (patch); Management of prostate cancer; Internal medicine; Oncology; Gonadotropin-releasing hormone; Androgen; Androgen suppression; Cancer; Luteinizing hormone; Endocrinology; Hormone","authors":[{"name":"Fred Saad","is_ca":true},{"name":"Neal D. Shore","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0585975078822475,"gpt":0.4545254438389683,"spread":0.3959279359567208,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001103759,0.0002713923,0.0003332537,0.0002856159,0.0001706715,0.0002416803,0.0002690843,0.000249452,0.001849406],"category_scores_gemma":[0.0001002924,0.00007316087,0.0003688174,0.0001774436,0.000132045,0.0002339283,0.0002835885,0.0008265521,0.0005165181],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001711487,"about_ca_system_score_gemma":0.0003108801,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004047164,"about_ca_topic_score_gemma":0.00160113,"domain_scores_codex":[0.9999442,0.00001179578,0.000004950018,0.00001120351,0.00001790323,0.000009958276],"domain_scores_gemma":[0.9999688,0.000003596663,0.000009574111,0.000001467598,0.000003329714,0.00001332778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003122661,0.001128917,0.001717962,0.002455081,0.0001899462,0.001029024,0.000122143,0.0006504675,0.05136162,0.001129459,0.01535219,0.9217406],"study_design_scores_gemma":[0.01397866,0.04588014,0.05040254,0.001102215,0.0008204578,0.03748771,0.0002025853,0.004180839,0.04702637,0.00222129,0.7964679,0.0002292162],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.4355199,0.5031688,0.01431057,0.006569081,0.001575334,0.001130296,0.001680065,0.001670014,0.03437592],"genre_scores_gemma":[0.803578,0.1569286,0.01523104,0.005610624,0.0009644875,0.00050662,0.002290007,0.0001002719,0.01479047],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001849406,"threshold_uncertainty_score":0.006186903,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3010740851","doi":"10.1177/1758835920909091","title":"Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Alberta Cancer Foundation; Mount Sinai Hospital; Dr. H. Bliss Murphy Cancer Centre; BC Cancer Agency","funders":"","keywords":"Atezolizumab; Medicine; Metastatic breast cancer; Pembrolizumab; Oncology; Internal medicine; Hazard ratio; Triple-negative breast cancer; Breast cancer; Population; Chemotherapy; Placebo; Progression-free survival; Clinical trial; Cancer; Immunotherapy; Confidence interval; Pathology","authors":[{"name":"Christine Simmons","is_ca":true},{"name":"Christine Brezden‐Masley","is_ca":true},{"name":"Joy McCarthy","is_ca":true},{"name":"Deanna McLeod","is_ca":false},{"name":"Anil A. Joy","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02692938279819948,"gpt":0.4086304143515668,"spread":0.3817010315533673,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007731426,0.0005240154,0.002049763,0.001386694,0.0002733714,0.002475634,0.001029233,0.001423733,0.003089272],"category_scores_gemma":[0.009206142,0.0002892748,0.001274899,0.001732673,0.001023209,0.003612124,0.0008361812,0.002415628,0.0005180879],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001210429,"about_ca_system_score_gemma":0.002834428,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001099278,"about_ca_topic_score_gemma":0.003029829,"domain_scores_codex":[0.9984352,0.0005450149,0.000327862,0.0001842026,0.0004379782,0.00006963662],"domain_scores_gemma":[0.990308,0.006644198,0.001294634,0.0001368217,0.001362019,0.000254372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000749919,0.00006389444,0.0008913946,0.04079111,0.0005095015,0.0001588545,0.0001650557,0.0004033007,0.0007147306,0.003974649,0.01320372,0.9383739],"study_design_scores_gemma":[0.0007270629,0.002125341,0.006714432,0.1118904,0.003881885,0.001642617,0.0009533985,0.0009171856,0.0008258651,0.01528856,0.8549328,0.0001004943],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002792042,0.9968768,0.00005214612,0.002326,0.0001648394,0.000003089038,0.00001434671,0.000003331041,0.0002801644],"genre_scores_gemma":[0.004869538,0.992243,0.0002219554,0.001838162,0.0006427403,0.000009268918,0.00002679044,0.000002558809,0.0001460377],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007731426,"threshold_uncertainty_score":0.04088813,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4409528322","doi":"10.1177/17588359251327992","title":"TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Chugai Pharmaceutical; Samsung; Aptitude Health; Astellas Pharma; Eisai; Relay Therapeutics; Seagen; Silverback Therapeutics; Daewoong Pharmaceutical Company; AstraZeneca España; Puma Biotechnology; Genentech; Veracyte; Mersana Therapeutics; Menarini Silicon Biosystems; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer; HCA Healthcare; Les Laboratories Pierre Fabre; G1 Therapeutics; Celgene; Carrick Therapeutics; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Durvalumab; Gemcitabine; Clinical endpoint; Internal medicine; Oncology; Carboplatin; Chemotherapy; Clinical trial; Cancer; Immunotherapy; Cisplatin","authors":[{"name":"Peter Schmid","is_ca":false},{"name":"Mafalda Oliveira","is_ca":false},{"name":"Joyce O’Shaughnessy","is_ca":false},{"name":"Massimo Cristofanilli","is_ca":false},{"name":"Stephanie L. Graff","is_ca":false},{"name":"Seock-Ah Im","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"Shigehira Saji","is_ca":false},{"name":"Shusen Wang","is_ca":false},{"name":"David W. Cescon","is_ca":true},{"name":"Tina Hovey","is_ca":false},{"name":"Agata Nawrot","is_ca":false},{"name":"KY Tse","is_ca":false},{"name":"Petra Vuković","is_ca":false},{"name":"Giuseppe Curigliano","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03195292858781053,"gpt":0.4375393702416746,"spread":0.405586441653864,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002428378,0.002235773,0.002892884,0.0004834323,0.0004951491,0.001335595,0.001430555,0.001848342,0.006859031],"category_scores_gemma":[0.001607354,0.0009342381,0.00170538,0.000466582,0.001561766,0.001270771,0.000507238,0.003640113,0.001483547],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001258262,"about_ca_system_score_gemma":0.001976916,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001331439,"about_ca_topic_score_gemma":0.003227825,"domain_scores_codex":[0.9992658,0.0003821921,0.00003017065,0.0001125209,0.00004952799,0.0001597574],"domain_scores_gemma":[0.9986972,0.0002557101,0.0002538218,0.00008439728,0.00006237206,0.0006465008],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9613875,0.02162507,0.0006759585,0.0002669716,0.000412887,0.00003374549,0.00005152221,0.0003909007,0.003636,0.0001208763,0.0007955839,0.01060288],"study_design_scores_gemma":[0.8735855,0.1235989,0.001022499,0.00001396465,0.0002265979,0.00003148294,0.00002268839,0.0003922464,0.0004529009,0.00009700029,0.0005443131,0.00001191672],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863384,0.001975231,0.0006245662,0.0008303358,0.0005906888,0.005968989,0.001448901,0.0001246909,0.002098236],"genre_scores_gemma":[0.9783571,0.002138917,0.002173804,0.00200752,0.000572711,0.007691466,0.002015121,0.00003932555,0.005003976],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006859031,"threshold_uncertainty_score":0.02294576,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2113562909","doi":"10.1177/1758834009352498","title":"Review: Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions","year":2009,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; BC Cancer Agency","funders":"","keywords":"Temsirolimus; Pazopanib; Medicine; Axitinib; Sorafenib; Sunitinib; Bevacizumab; Everolimus; Renal cell carcinoma; Targeted therapy; Oncology; PI3K/AKT/mTOR pathway; Adjuvant; Clinical trial; Vascular endothelial growth factor; Adjuvant therapy; Internal medicine; Pharmacology; Discovery and development of mTOR inhibitors; Cancer; VEGF receptors; Chemotherapy","authors":[{"name":"Daniel Y.C. Heng","is_ca":true},{"name":"Christian Kollmannsberger","is_ca":true},{"name":"Kim N.","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03495072061428077,"gpt":0.3814300607698013,"spread":0.3464793401555206,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001136237,0.00104846,0.002239981,0.001632774,0.0003914931,0.001418323,0.001556379,0.0022055,0.009713172],"category_scores_gemma":[0.00224303,0.0002122513,0.0006933933,0.002358574,0.0006979041,0.002578041,0.0005168979,0.002171854,0.006410961],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008260026,"about_ca_system_score_gemma":0.001316065,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001186937,"about_ca_topic_score_gemma":0.002420551,"domain_scores_codex":[0.9995271,0.0001582408,0.00007507022,0.00005312884,0.0001550902,0.00003135071],"domain_scores_gemma":[0.9986234,0.0006427426,0.0001422324,0.00002649921,0.0004236998,0.0001415059],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002079848,0.00008383558,0.0002019778,0.0137644,0.0001000708,0.0003801574,0.00003152884,0.0003393494,0.0005317511,0.001182114,0.3207904,0.6623864],"study_design_scores_gemma":[0.00008025354,0.0001352202,0.0008439049,0.005158461,0.0001459192,0.002202554,0.00005872751,0.0001070208,0.0001183729,0.00137142,0.98976,0.00001820456],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009525067,0.991996,0.0002023158,0.003047745,0.003185073,0.0000173705,0.00002971118,0.00001395883,0.001412538],"genre_scores_gemma":[0.0005624783,0.9925693,0.0002986027,0.002260898,0.002893453,0.00002063453,0.00004949514,0.000003924998,0.001341298],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.009713172,"threshold_uncertainty_score":0.03249383,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4296502312","doi":"10.1177/17588359221126151","title":"Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Lung cancer; Internal medicine; Biopsy; Referral; Liquid biopsy; Cancer; Oncology; Clinical endpoint; Cohort study; Pathology; Clinical trial","authors":[{"name":"Miguel García-Pardo","is_ca":true},{"name":"Kasia Czarnecka","is_ca":true},{"name":"Jennifer Law","is_ca":true},{"name":"Alexandra Salvarrey","is_ca":true},{"name":"Roxanne Fernandes","is_ca":true},{"name":"Jason Fan","is_ca":true},{"name":"Lucy Corke","is_ca":true},{"name":"Thomas K. Waddell","is_ca":true},{"name":"Kazuhiro Yasufuku","is_ca":true},{"name":"Laura Donahoe","is_ca":true},{"name":"Andrew Pierre","is_ca":true},{"name":"Lisa W. Le","is_ca":true},{"name":"Noor Ghumman","is_ca":true},{"name":"Geoffrey Liu","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Penelope A. Bradbury","is_ca":true},{"name":"Adrian G. Sacher","is_ca":true},{"name":"Tracy Stockley","is_ca":true},{"name":"Prodipto Pal","is_ca":true},{"name":"Patrik Rogalla","is_ca":true},{"name":"Ming‐Sound Tsao","is_ca":true},{"name":"Natasha B. Leighl","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01814273573074241,"gpt":0.3462831243431265,"spread":0.3281403886123841,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002405568,0.0005226244,0.0005898185,0.001168788,0.0003244906,0.001557415,0.00124754,0.0006786107,0.004911715],"category_scores_gemma":[0.002835554,0.0003809782,0.0004115359,0.0005703486,0.0003793245,0.001087234,0.001513242,0.0009345159,0.001846557],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008510147,"about_ca_system_score_gemma":0.001058395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002158447,"about_ca_topic_score_gemma":0.002609528,"domain_scores_codex":[0.9986857,0.0004262348,0.00004487994,0.0003117449,0.0004408719,0.00009062643],"domain_scores_gemma":[0.9984888,0.0005636634,0.0003061234,0.0001438502,0.0003072302,0.0001903035],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004769658,0.0007593093,0.1577941,0.001033474,0.000298968,0.0008222592,0.0002757567,0.003878026,0.1393374,0.001661923,0.02230358,0.6670656],"study_design_scores_gemma":[0.002332198,0.01349902,0.3424445,0.001132926,0.0008853119,0.02342436,0.0007722115,0.1644398,0.2998903,0.007192705,0.1435156,0.0004710765],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.6412547,0.0287048,0.2872308,0.006908712,0.001136064,0.001412714,0.004468762,0.01329855,0.01558499],"genre_scores_gemma":[0.8044612,0.00400676,0.1810537,0.001963253,0.0005900324,0.0005063285,0.003018059,0.0004118199,0.003988713],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.004911715,"threshold_uncertainty_score":0.01643133,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2166720958","doi":"10.1177/1758834011399306","title":"Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tolerability; Lung cancer; Regimen; Oncology; Maintenance therapy; Intensive care medicine; Chemotherapy; Immunotherapy; Disease; Internal medicine; Clinical trial; Cancer; Adverse effect","authors":[{"name":"Linda Coate","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01875366617280496,"gpt":0.3790955163536733,"spread":0.3603418501808683,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008848314,0.0001091989,0.0005467776,0.0001647156,0.0001707676,0.0003026558,0.0002154351,0.0003077636,0.000794546],"category_scores_gemma":[0.0007924599,0.00003560599,0.0003443295,0.0002934985,0.0001322947,0.0003654078,0.0001325624,0.0005537666,0.0001319305],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003605533,"about_ca_system_score_gemma":0.000192773,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003269266,"about_ca_topic_score_gemma":0.0008645131,"domain_scores_codex":[0.9998357,0.00006330546,0.00001803705,0.00001782448,0.00004361655,0.00002146893],"domain_scores_gemma":[0.9996281,0.0001389827,0.0001166171,0.00002359625,0.00003045339,0.0000621839],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01580996,0.00193169,0.04938954,0.000700867,0.0002983971,0.0004710326,0.0002759675,0.001120834,0.02246094,0.0005808566,0.002438363,0.9045216],"study_design_scores_gemma":[0.005513052,0.2021157,0.7139797,0.000498878,0.001192721,0.00677509,0.0003130473,0.003958372,0.01590884,0.002159982,0.04752562,0.0000589361],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.9126918,0.08125783,0.001010116,0.001074732,0.00005301007,0.000144033,0.0002556123,0.00004302768,0.003469925],"genre_scores_gemma":[0.9857317,0.01152838,0.0007627854,0.0004841554,0.000111032,0.00006799099,0.000448409,0.000009287148,0.0008562595],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.0008848314,"threshold_uncertainty_score":0.004679501,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4407230737","doi":"10.1177/17588359251316176","title":"TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"Genentech; Astellas Pharma; Daiichi-Sankyo; Natera; Puma Biotechnology; Syndax Pharmaceuticals; Chugai Pharmaceutical; Nihon Medi-Physics; Eisai; Jazz Pharmaceuticals; Incyte; Taiho Pharmaceutical; Spectrum Pharmaceuticals; Boston Scientific Corporation; Gilead Sciences; Exelixis; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Pembrolizumab; Internal medicine; Breast cancer; Chemotherapy; Clinical endpoint; Oncology; Adjuvant; Triple-negative breast cancer; Cancer; Clinical trial; Immunotherapy","authors":[{"name":"Heather L. McArthur","is_ca":false},{"name":"Sara M. Tolaney","is_ca":false},{"name":"Rebecca Dent","is_ca":false},{"name":"Peter Schmid","is_ca":false},{"name":"Jamil Asselah","is_ca":true},{"name":"Qiang Liu","is_ca":false},{"name":"Jane Meisel","is_ca":false},{"name":"Naoki Niikura","is_ca":false},{"name":"Gustavo Werutsky","is_ca":false},{"name":"Giampaolo Bianchini","is_ca":false},{"name":"Jay C. Andersen","is_ca":false},{"name":"Robert Kozarski","is_ca":false},{"name":"Nana Rokutanda","is_ca":false},{"name":"Barbara Pistilli","is_ca":false},{"name":"Sibylle Loibl","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01792386089167593,"gpt":0.4126227275079166,"spread":0.3946988666162407,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003205957,0.002715067,0.002935334,0.0006019558,0.0005003187,0.001216924,0.001534911,0.001894196,0.008653352],"category_scores_gemma":[0.001984859,0.0009459492,0.001808996,0.000597922,0.00175423,0.001382666,0.0005527668,0.003495924,0.001440027],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001327202,"about_ca_system_score_gemma":0.0023145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001316682,"about_ca_topic_score_gemma":0.002935353,"domain_scores_codex":[0.9990232,0.0005882219,0.00003910298,0.0001236177,0.00006245291,0.0001635092],"domain_scores_gemma":[0.9985396,0.0002962081,0.0003303347,0.0001209531,0.00008303214,0.0006298178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9586334,0.02319466,0.0007720438,0.0003723535,0.000396912,0.00003002264,0.00005122241,0.000404527,0.003551559,0.0001233092,0.0008793705,0.01159071],"study_design_scores_gemma":[0.8579628,0.1393965,0.0009706487,0.00001572659,0.0002042998,0.00002913325,0.00002016457,0.0002784634,0.0004386487,0.00008240982,0.00058977,0.00001132711],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9805014,0.002207182,0.0008614084,0.0007501349,0.000542436,0.0106489,0.002068118,0.000168876,0.0022515],"genre_scores_gemma":[0.9620349,0.00311187,0.003912147,0.002071975,0.0007209731,0.01775485,0.003114443,0.00006685443,0.007211949],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008653352,"threshold_uncertainty_score":0.02894831,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4205192276","doi":"10.1177/17588359211072621","title":"Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Instituto de Salud Carlos III; Junta de Comunidades de Castilla-La Mancha","keywords":"Immunoglobulin superfamily; Carcinoembryonic antigen; Medicine; Cell adhesion molecule; Immune system; Antibody; Cancer research; Cell adhesion; Cancer; Immunology; Oncology; Cell; Bioinformatics; Internal medicine; Biology; Genetics","authors":[{"name":"Miguel Burgos","is_ca":false},{"name":"Iván Cavero‐Redondo","is_ca":false},{"name":"Celia Álvarez‐Bueno","is_ca":false},{"name":"Eva María Galán‐Moya","is_ca":false},{"name":"Atanasio Pandiella","is_ca":false},{"name":"Eitan Amir","is_ca":true},{"name":"Alberto Ocaña","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05935806131821707,"gpt":0.4326514725263498,"spread":0.3732934112081328,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007937781,0.001858846,0.01073254,0.003437825,0.0006180159,0.002478346,0.001471038,0.001635114,0.002863363],"category_scores_gemma":[0.01406379,0.0009082719,0.03787074,0.005363242,0.0004765211,0.0009434277,0.001125557,0.001654745,0.0002724381],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001045386,"about_ca_system_score_gemma":0.001268918,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004876584,"about_ca_topic_score_gemma":0.006152966,"domain_scores_codex":[0.9944846,0.002486672,0.001080095,0.001084198,0.0005612124,0.00030314],"domain_scores_gemma":[0.987944,0.008979042,0.001456284,0.0007320954,0.0006630404,0.0002255296],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.005629566,0.00003033671,0.04067884,0.04846447,0.894417,0.0001908561,0.00004405453,0.001468129,0.0005518386,0.0001051508,0.0006816949,0.007738027],"study_design_scores_gemma":[0.0004659863,0.0002330269,0.01593885,0.001889699,0.9795821,0.0001105887,0.00002101158,0.0005796609,0.0001563714,0.0001698843,0.0008355547,0.00001724394],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.05491286,0.9392118,0.001854884,0.0004209082,0.0002857696,0.0001580477,0.002418475,0.00008094997,0.0006563345],"genre_scores_gemma":[0.8216114,0.1719424,0.00205489,0.0007028374,0.0003743829,0.0004481802,0.002273932,0.00007474644,0.0005173208],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01073254,"threshold_uncertainty_score":0.04197949,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4327652478","doi":"10.1177/17588359231160141","title":"Direct GDP-KRAS <sup>G12C</sup> inhibitors and mechanisms of resistance: the tip of the iceberg","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Regeneron Pharmaceuticals; Sanofi; Daiichi-Sankyo; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; KRAS; Iceberg; Cancer research; Internal medicine; Pharmacology; Cancer; Physics","authors":[{"name":"Joshua C. Rosen","is_ca":true},{"name":"Adrian G. Sacher","is_ca":true},{"name":"Ming‐Sound Tsao","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02494405273547091,"gpt":0.3498188310208574,"spread":0.3248747782853865,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007707488,0.0004503959,0.001011612,0.0007280657,0.0003115424,0.001756086,0.0004328043,0.001051119,0.001660335],"category_scores_gemma":[0.0006155962,0.0002855661,0.0003810581,0.0006628633,0.001111559,0.002395221,0.0006078123,0.002791317,0.001445593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001055943,"about_ca_system_score_gemma":0.0006636546,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004332567,"about_ca_topic_score_gemma":0.0009859214,"domain_scores_codex":[0.9997491,0.00005529073,0.00003036312,0.00003781372,0.00008208431,0.00004525981],"domain_scores_gemma":[0.9997174,0.0001247516,0.00004854404,0.00001619482,0.00006331469,0.00002977785],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000751953,0.0001589205,0.001384642,0.007887148,0.0001300763,0.0009747474,0.0003724202,0.00217743,0.05483291,0.06308847,0.04397195,0.8242692],"study_design_scores_gemma":[0.0000410789,0.0005080228,0.001912114,0.0009461464,0.00008054533,0.002397159,0.0002415541,0.0008495247,0.02121333,0.02811606,0.9436384,0.00005601989],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.004426337,0.9810477,0.002177068,0.008209056,0.0005437137,0.00001114943,0.00005911913,0.00007783688,0.003448083],"genre_scores_gemma":[0.02006916,0.9711473,0.001606458,0.002779707,0.0006656311,0.00002519631,0.0001208617,0.00002953598,0.003556117],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001756086,"threshold_uncertainty_score":0.007661402,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379383902","doi":"10.1177/17588359231175440","title":"Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency; Ottawa Hospital; Sinai Health System; University of Toronto; University of Alberta; University of Calgary","funders":"National Cancer Institute; Mylan; AstraZeneca Canada; Seagen; Gilead Sciences; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Metastatic breast cancer; Internal medicine; Clinical trial; Biomarker; Disease; Hormone receptor; Pertuzumab; Cancer; Population; Human Epidermal Growth Factor Receptor 2","authors":[{"name":"Charlie Yang","is_ca":true},{"name":"Christine Brezden‐Masley","is_ca":true},{"name":"Anil A. Joy","is_ca":true},{"name":"Sandeep Sehdev","is_ca":true},{"name":"Shanu Modi","is_ca":false},{"name":"Christine Simmons","is_ca":true},{"name":"Jan‐Willem Henning","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1399657081691481,"gpt":0.5367814479793399,"spread":0.3968157398101919,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001705392,0.0005937441,0.001762669,0.001528291,0.0002123554,0.001343416,0.001034332,0.00112377,0.002373081],"category_scores_gemma":[0.001256193,0.0002102604,0.0006036873,0.001461899,0.0005734015,0.001777895,0.0006777017,0.003059426,0.001227523],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007323913,"about_ca_system_score_gemma":0.001267811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008113477,"about_ca_topic_score_gemma":0.00253649,"domain_scores_codex":[0.9997204,0.00009167896,0.00004114465,0.00004128596,0.00007972099,0.00002575118],"domain_scores_gemma":[0.9993255,0.00041999,0.00006687,0.00001375604,0.0001371064,0.00003683015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001282519,0.00007214268,0.0001270907,0.01661779,0.0001154375,0.000144638,0.00006019813,0.0004080052,0.000811387,0.007723448,0.01953699,0.9542545],"study_design_scores_gemma":[0.00007810249,0.0002672939,0.0005799297,0.01105877,0.0002136504,0.001067397,0.0001049815,0.0002175946,0.0003080709,0.004879908,0.9812024,0.00002186737],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007934044,0.9985709,0.00007308522,0.0007483986,0.0001029462,0.000003290408,0.000008336096,0.000003696588,0.0004098925],"genre_scores_gemma":[0.0005527016,0.9985531,0.0001301961,0.0004549303,0.0001278818,0.000004905492,0.00001298825,0.000001236747,0.0001621278],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002373081,"threshold_uncertainty_score":0.009019077,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3203798531","doi":"10.1177/17588359211039928","title":"ALBI score and outcomes in patients with hepatocellular carcinoma: <i>post hoc</i> analysis of the randomized controlled trial KEYNOTE-240","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Post-hoc analysis; Internal medicine; Placebo; Pembrolizumab; Hazard ratio; Hepatocellular carcinoma; Confidence interval; Hepatology; Gastroenterology; Liver function; Sorafenib; Cancer; Pathology","authors":[{"name":"Arndt Vogel","is_ca":false},{"name":"Philippe Merle","is_ca":false},{"name":"Chris Verslype","is_ca":false},{"name":"Richard S. Finn","is_ca":false},{"name":"Andrew X. Zhu","is_ca":false},{"name":"Ann‐Lii Cheng","is_ca":false},{"name":"Stephen L. Chan","is_ca":false},{"name":"Thomas Yau","is_ca":false},{"name":"Baek‐Yeol Ryoo","is_ca":false},{"name":"Jennifer J. Knox","is_ca":true},{"name":"Bruno Daniele","is_ca":false},{"name":"Shukui Qin","is_ca":false},{"name":"Ziwen Wei","is_ca":false},{"name":"Yanna R. Miteva","is_ca":false},{"name":"Usha Malhotra","is_ca":false},{"name":"Abby B. Siegel","is_ca":false},{"name":"Masatoshi Kudo","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01850701140717144,"gpt":0.2851676526289131,"spread":0.2666606412217417,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0101304,0.002618701,0.005282288,0.0005256971,0.0003732307,0.001941892,0.001232227,0.001579896,0.007829404],"category_scores_gemma":[0.009147299,0.0008340553,0.008148788,0.000480043,0.001136144,0.001351114,0.0008002414,0.003256184,0.0007451639],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001184726,"about_ca_system_score_gemma":0.001467057,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006615678,"about_ca_topic_score_gemma":0.0009405813,"domain_scores_codex":[0.9933164,0.004872047,0.0003281295,0.000714829,0.0002894501,0.0004792229],"domain_scores_gemma":[0.9919088,0.004291793,0.001853648,0.0008353246,0.0004726079,0.0006377356],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.9868106,0.0007698627,0.0007528875,0.000514027,0.007202109,0.00002114036,0.00001396982,0.000309067,0.0005140209,0.00005538863,0.0004431213,0.002593818],"study_design_scores_gemma":[0.8885378,0.0839135,0.006662224,0.00008897112,0.01662585,0.00004930679,0.00003176704,0.001722929,0.001014063,0.0003309346,0.000981134,0.00004153319],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.973916,0.008874614,0.002565981,0.00106836,0.001523625,0.004947658,0.003292226,0.000329512,0.003482188],"genre_scores_gemma":[0.9877702,0.001207973,0.001828162,0.000770812,0.0007397939,0.003966359,0.001533927,0.00006097255,0.002121799],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0101304,"threshold_uncertainty_score":0.05357528,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3129833506","doi":"10.1177/1758835921992987","title":"Elevated risk of colorectal, liver, and pancreatic cancers among HCV, HBV and/or HIV (co)infected individuals in a population based cohort in Canada","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Simon Fraser University; Vancouver General Hospital; University of Waterloo; BC Centre for Disease Control; University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Medicine; Internal medicine; Hepatitis C virus; Pancreatic cancer; Colorectal cancer; Gastroenterology; Population; Cohort; Hazard ratio; Liver cancer; Hepatitis B virus; Hepatitis C; Cancer; Hepatitis B; Confidence interval; Immunology; Virus","authors":[{"name":"Maryam Darvishian","is_ca":true},{"name":"Zahid A Butt","is_ca":true},{"name":"Stanley Wong","is_ca":true},{"name":"Eric M. Yoshida","is_ca":true},{"name":"Jaskaran Khinda","is_ca":true},{"name":"Michael Otterstatter","is_ca":true},{"name":"Amanda Yu","is_ca":true},{"name":"Mawuena Binka","is_ca":true},{"name":"Carmine Rossi","is_ca":true},{"name":"Geoffrey McKee","is_ca":true},{"name":"Margo Pearce","is_ca":true},{"name":"Maria Alvarez","is_ca":true},{"name":"Jason Wong","is_ca":true},{"name":"Darrel Cook","is_ca":true},{"name":"Troy Grennan","is_ca":true},{"name":"Jane A. Buxton","is_ca":true},{"name":"Mark Tyndall","is_ca":true},{"name":"Ryan Woods","is_ca":true},{"name":"Mel Krajden","is_ca":true},{"name":"Parveen Bhatti","is_ca":true},{"name":"Naveed Z. Janjua","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01511866858711174,"gpt":0.319809794254882,"spread":0.3046911256677703,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002552443,0.0002674953,0.0003137777,0.0009205851,0.001529156,0.0009793055,0.0005827767,0.0002592213,0.001648273],"category_scores_gemma":[0.0006782202,0.0003380373,0.000392322,0.002199104,0.0004681464,0.0001881008,0.0005749996,0.0005288291,0.0001446428],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006934342,"about_ca_system_score_gemma":0.01087148,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.97527,"about_ca_topic_score_gemma":0.9784812,"domain_scores_codex":[0.999622,0.00002398978,0.00001949998,0.00007161253,0.0001361298,0.0001267379],"domain_scores_gemma":[0.9992829,0.00003379561,0.0001658421,0.0000303964,0.000243434,0.0002436096],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00004734115,0.000006665749,0.9981053,0.00001188703,0.0000333127,0.00008025914,0.0001351884,0.00005028268,0.000179772,0.00002686256,0.0002683008,0.00105477],"study_design_scores_gemma":[0.000005046772,0.00001250051,0.9988643,0.00001318437,0.00003008338,0.0001385206,0.0003015955,0.000206589,0.00004468832,0.00002337392,0.0003544641,0.000005681266],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956372,0.0006253489,0.0001056381,0.0001655836,0.000007106067,0.00001944948,0.002188877,0.000011098,0.001239659],"genre_scores_gemma":[0.9982876,0.0004504732,0.00008885186,0.00003400287,0.00000283962,0.000004656015,0.0007295168,0.00000219014,0.0003997381],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02473003,"threshold_uncertainty_score":0.0503124,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4205632236","doi":"10.1177/17588359211059601","title":"Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline <i>BRCA1</i> / <i>2</i> mutations and hormone receptor status from the phase-3 BROCADE3 trial","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Aptitude Health; AbbVie","keywords":"Hazard ratio; Veliparib; Breast cancer; Metastatic breast cancer; Clinical endpoint; Placebo; BRCA mutation; Germline mutation","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.026685671906535,"gpt":0.392095379246344,"spread":0.365409707339809,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001786605,0.000838923,0.002153897,0.0002978733,0.0002306659,0.001003654,0.0006348145,0.0008021738,0.001620614],"category_scores_gemma":[0.001620148,0.0003250975,0.002499695,0.0003947649,0.0004640002,0.00048338,0.0002550213,0.001564303,0.000248897],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005996727,"about_ca_system_score_gemma":0.000824848,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000496249,"about_ca_topic_score_gemma":0.001392885,"domain_scores_codex":[0.9992956,0.0004262662,0.00006167787,0.00009676944,0.00005278416,0.00006688343],"domain_scores_gemma":[0.9992959,0.0002141927,0.0002277989,0.00006906028,0.00003744044,0.0001555539],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9552673,0.002228612,0.006232963,0.0005914138,0.005364366,0.00008066934,0.00006329219,0.001099889,0.005407739,0.00006170651,0.0006522577,0.02294971],"study_design_scores_gemma":[0.8795748,0.08207787,0.02671492,0.0001035135,0.006329554,0.0002231437,0.00006909953,0.001761495,0.001614676,0.0003299577,0.001164288,0.00003673809],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904196,0.007325177,0.0002680342,0.0003059482,0.00008760022,0.000445225,0.0004044606,0.00002731004,0.0007166102],"genre_scores_gemma":[0.996927,0.001375817,0.0002453297,0.0002770559,0.0001067336,0.0002593361,0.0005256619,0.000008520642,0.0002746763],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002153897,"threshold_uncertainty_score":0.009448588,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4295904913","doi":"10.1177/17588359221122714","title":"The role of gut microbiome in immune modulation in metastatic renal cell carcinoma","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Microbiome; Immunotherapy; Renal cell carcinoma; Gut microbiome; Immune system; Intensive care medicine; Gut flora; Immunology; Oncology; Bioinformatics; Biology","authors":[{"name":"Jasna Deluce","is_ca":true},{"name":"Saman Maleki Vareki","is_ca":true},{"name":"Ricardo Fernandes","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0327534350615301,"gpt":0.37980260325678,"spread":0.3470491681952499,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003357638,0.0004768937,0.0007410305,0.0009643275,0.0001847338,0.0007280497,0.0002920278,0.0006927117,0.002195582],"category_scores_gemma":[0.0006038429,0.0001148966,0.0004540096,0.0008269823,0.0002157965,0.0006603877,0.0005162235,0.0009127212,0.0007093293],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003496297,"about_ca_system_score_gemma":0.000869357,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009132095,"about_ca_topic_score_gemma":0.001532466,"domain_scores_codex":[0.999884,0.00003501557,0.00001550597,0.00001696931,0.00003446294,0.00001406966],"domain_scores_gemma":[0.9998522,0.00007426826,0.00002279891,0.000003722366,0.0000347999,0.00001226851],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001098672,0.00005155485,0.0003903825,0.02123771,0.0001662468,0.0001780191,0.0000766156,0.0003284009,0.002383224,0.003147962,0.02296728,0.9489628],"study_design_scores_gemma":[0.00002748581,0.0001817321,0.003692906,0.0106891,0.0002848783,0.001687946,0.0001197327,0.0002272505,0.0008883396,0.002917878,0.9792528,0.00002983153],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002174968,0.9985215,0.0001049484,0.0003741086,0.0001877139,0.000003275421,0.00001832824,0.000004959837,0.0005675165],"genre_scores_gemma":[0.00135012,0.9978004,0.0001292008,0.0001835881,0.0001356739,0.000004629318,0.00002293273,9.718514e-7,0.0003723561],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002195582,"threshold_uncertainty_score":0.007345021,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4286357580","doi":"10.1177/17588359221111705","title":"Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"BC Cancer Agency; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; Queen Elizabeth II Health Sciences Centre; William Osler Health System; University of Alberta; Surrey Memorial Hospital","funders":"Pfizer Canada; Amgen Canada; Thermo Scientific","keywords":"KRAS; Medicine; Colorectal cancer; Biomarker; Oncology; Guideline; Targeted therapy; Biomarker discovery; Cancer; Internal medicine; Bioinformatics; Pathology; Gene; Biology","authors":[{"name":"Irene Yu","is_ca":true},{"name":"Rachel Goodwin","is_ca":true},{"name":"Jonathan M. Loree","is_ca":true},{"name":"Cheryl Mather","is_ca":true},{"name":"Brandon S. Sheffield","is_ca":true},{"name":"Stephanie Snow","is_ca":true},{"name":"Sharlene Gill","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1339412313251146,"gpt":0.491445212441576,"spread":0.3575039811164614,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008160821,0.001214018,0.002374782,0.006725371,0.001088752,0.002093689,0.005069468,0.004338569,0.004900685],"category_scores_gemma":[0.01251817,0.000605556,0.003061066,0.006711469,0.001276686,0.001628191,0.001708908,0.004351512,0.003057569],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.011927,"about_ca_system_score_gemma":0.04547409,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.2302746,"about_ca_topic_score_gemma":0.3522631,"domain_scores_codex":[0.9953235,0.0009770652,0.000938277,0.0002242444,0.002232341,0.0003046537],"domain_scores_gemma":[0.9873203,0.001914544,0.0008559289,0.0001744314,0.009215373,0.0005194505],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000768438,0.00006506069,0.0006899007,0.01991958,0.0001832116,0.0003294232,0.0001970495,0.0005052097,0.0006413175,0.005151129,0.5071535,0.4650878],"study_design_scores_gemma":[0.00009312727,0.00003009227,0.002061519,0.02784347,0.0003013591,0.0005900809,0.0001038108,0.000229601,0.0002204025,0.002429722,0.9660516,0.00004520707],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004522001,0.8915928,0.004685184,0.06439462,0.004474918,0.001338525,0.003992877,0.0002189674,0.0288499],"genre_scores_gemma":[0.005203848,0.928505,0.02253668,0.02552668,0.001028992,0.001088264,0.006933132,0.0000527353,0.009124693],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7697254,"threshold_uncertainty_score":0.4578684,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3195299022","doi":"10.1177/17588359211039052","title":"Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Urothelial carcinoma; Carcinoma; Cancer research; Oncology; Bladder cancer; Internal medicine; Cancer","authors":[{"name":"Omid Yassaie","is_ca":true},{"name":"Cyrus Chehroudi","is_ca":true},{"name":"Peter C. Black","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09591219510996234,"gpt":0.4072967351049521,"spread":0.3113845399949898,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003972002,0.000588707,0.0009656914,0.001908103,0.0002294411,0.000744273,0.0006259612,0.0006804253,0.003112624],"category_scores_gemma":[0.0004879273,0.0001938483,0.0006320282,0.001404551,0.0003190481,0.0009752454,0.0005510227,0.001552391,0.001095916],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004053946,"about_ca_system_score_gemma":0.0007060529,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008201986,"about_ca_topic_score_gemma":0.001877676,"domain_scores_codex":[0.9998406,0.0000309667,0.00002477376,0.00002661763,0.00005863806,0.00001836439],"domain_scores_gemma":[0.9998391,0.0000802955,0.0000261487,0.000004457419,0.00003800186,0.00001197087],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006390249,0.00007479035,0.0001368607,0.02445433,0.00009955193,0.0001996276,0.00006711615,0.0004341475,0.002246405,0.002766981,0.01365744,0.955799],"study_design_scores_gemma":[0.00002862565,0.0001849012,0.001117442,0.007087573,0.000188109,0.001818315,0.00008493723,0.0001789921,0.0006933562,0.002116432,0.9864796,0.00002179343],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001383322,0.9988092,0.0001099236,0.0001541992,0.0001039665,0.000004592037,0.0000108688,0.000005116382,0.000663756],"genre_scores_gemma":[0.0006671831,0.9986812,0.0001630182,0.0001264787,0.00007751885,0.000004653455,0.00002018814,9.95413e-7,0.0002586669],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003112624,"threshold_uncertainty_score":0.01041275,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4323063328","doi":"10.1177/17588359231157651","title":"Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver General Hospital; University of British Columbia Hospital; University of British Columbia; Pancreas Centre (Canada)","funders":"Terry Fox Research Institute; Genome British Columbia; Pancreatic Cancer Canada Foundation; VGH and UBC Hospital Foundation","keywords":"Liquid biopsy; Medicine; Pancreatic ductal adenocarcinoma; Druggability; Pancreatic cancer; Disease; Clinical trial; Genomics; Bioinformatics; Internal medicine; Oncology; Cancer; Genome; Gene; Biology; Genetics","authors":[{"name":"James T. Topham","is_ca":true},{"name":"Daniel J. Renouf","is_ca":true},{"name":"David F. Schaeffer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08646251333694421,"gpt":0.4371774313894952,"spread":0.350714918052551,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001285975,0.0006032989,0.001147082,0.001981197,0.0002365827,0.001269187,0.0008353892,0.001205162,0.001395413],"category_scores_gemma":[0.00130902,0.0002481061,0.0004750666,0.001431594,0.0008699894,0.001905687,0.0008895218,0.002996103,0.001144919],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001041249,"about_ca_system_score_gemma":0.001454558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009676836,"about_ca_topic_score_gemma":0.001651999,"domain_scores_codex":[0.9996978,0.00008161847,0.00004197938,0.00004818085,0.0001071058,0.00002329456],"domain_scores_gemma":[0.9993755,0.0003536603,0.00004985707,0.00001624387,0.0001609027,0.00004388958],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007459271,0.00005254307,0.0002679529,0.009402675,0.00006627792,0.0002700244,0.00009054022,0.0004318413,0.00149789,0.01288794,0.02832396,0.9466337],"study_design_scores_gemma":[0.00001579427,0.00009006307,0.0006209148,0.00303378,0.00005814133,0.001333453,0.00006677338,0.0001672326,0.0004764436,0.005504154,0.988611,0.00002215957],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000819612,0.9977263,0.0002485917,0.001029045,0.0002715393,0.000003032265,0.000009283529,0.000006954056,0.0006234539],"genre_scores_gemma":[0.0007339432,0.9976404,0.0002956657,0.0006274885,0.0003827726,0.000006674243,0.00001754526,0.000001914655,0.0002936834],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001981197,"threshold_uncertainty_score":0.007554829,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4361988864","doi":"10.1177/17588359231156382","title":"A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"FP7 Health; Pharmacyclics; Sanofi Genzyme; Genentech; Daiichi Sankyo Europe; National Cancer Institute; Servier; AstraZeneca; Institut National Du Cancer; Canadian Cancer Society; Foundation Medicine; Fondation ARC pour la Recherche sur le Cancer; Seagen; Puma Biotechnology; Actuate Therapeutics; Symphogen; Pfizer; Incyte; Grifols; EQRx; BeiGene; European Commission; Sanofi; Halozyme; Chugai Pharmaceutical; Israel Science Foundation; Ipsen; Array BioPharma; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Instituto de Salud Carlos III; Amgen; Novartis Pharmaceuticals Corporation; Les Laboratories Pierre Fabre","keywords":"Medicine; Oncology; Clinical trial; Internal medicine; Immunotherapy; Metastasis; Cancer","authors":[{"name":"Vladimir Lazar","is_ca":false},{"name":"Baolin Zhang","is_ca":false},{"name":"Shai Magidi","is_ca":false},{"name":"Christophe Le Tourneau","is_ca":false},{"name":"Eric Raymond","is_ca":false},{"name":"Michel Ducreux","is_ca":false},{"name":"Catherine Bresson","is_ca":false},{"name":"Jacques Raynaud","is_ca":false},{"name":"Fanny Wunder","is_ca":false},{"name":"Amir Onn","is_ca":false},{"name":"Enriqueta Felip","is_ca":false},{"name":"Josep Tabernero","is_ca":false},{"name":"Gerald Batist","is_ca":true},{"name":"Razelle Kurzrock","is_ca":false},{"name":"Eitan Rubin","is_ca":false},{"name":"Richard L. Schilsky","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1778064220423873,"gpt":0.5108081939300281,"spread":0.3330017718876408,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004589919,0.0008649275,0.001192407,0.001139376,0.0003943861,0.002289472,0.001065976,0.001333234,0.006038766],"category_scores_gemma":[0.006953433,0.0007982338,0.001457192,0.0009148369,0.001189902,0.001953143,0.001006896,0.001867158,0.001359732],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001805961,"about_ca_system_score_gemma":0.0023281,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001097355,"about_ca_topic_score_gemma":0.00151127,"domain_scores_codex":[0.9986429,0.0008082493,0.00006812815,0.0002219942,0.0001990889,0.00005974074],"domain_scores_gemma":[0.9966726,0.002327893,0.0003432009,0.0003627666,0.0001803939,0.00011303],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","study_design_scores_codex":[0.00122448,0.0005827324,0.01397708,0.0021122,0.0006701905,0.000399536,0.0003321763,0.3974912,0.1599341,0.194812,0.01196851,0.2164958],"study_design_scores_gemma":[0.0002617976,0.0008974185,0.003920533,0.0002690415,0.0003683404,0.000314031,0.0001692596,0.6069492,0.02102471,0.3036877,0.06202033,0.0001177985],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"methods","genre_gemma":"empirical","genre_scores_codex":[0.01828083,0.002001259,0.9645148,0.005104438,0.0003050971,0.0006100325,0.00211892,0.001608153,0.005456403],"genre_scores_gemma":[0.1875737,0.004629669,0.7972434,0.00234644,0.000326741,0.002254384,0.002073346,0.0002528721,0.003299464],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.006038766,"threshold_uncertainty_score":0.02427411,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4383647203","doi":"10.1177/17588359231183668","title":"Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Hospital; London Health Sciences Centre","funders":"","keywords":"SABR volatility model; Medicine; Lung cancer; Oncology; Clinical trial; Radiation therapy; Narrative review; Internal medicine; Medical physics; Intensive care medicine","authors":[{"name":"Sondos Zayed","is_ca":true},{"name":"Alexander V. Louie","is_ca":true},{"name":"Daniel Breadner","is_ca":true},{"name":"David A. Palma","is_ca":true},{"name":"Rohann Correa","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1472021680698072,"gpt":0.5244359166054591,"spread":0.3772337485356519,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009977097,0.0007875748,0.001611103,0.002611533,0.0002559718,0.0009985761,0.0009382984,0.001066248,0.003151236],"category_scores_gemma":[0.00119786,0.000306641,0.0008314117,0.002501724,0.0004069748,0.001397515,0.0006423273,0.001776268,0.001111512],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000562019,"about_ca_system_score_gemma":0.001489358,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009857715,"about_ca_topic_score_gemma":0.002696239,"domain_scores_codex":[0.9997541,0.00006218658,0.00005149714,0.00003643335,0.00007941688,0.0000163729],"domain_scores_gemma":[0.9994465,0.000346024,0.00008020199,0.00001072435,0.00009283837,0.00002379848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001208807,0.00007811408,0.0001172727,0.05407672,0.0002250963,0.0001635182,0.000076945,0.00034558,0.0008909031,0.003542832,0.02621485,0.9141473],"study_design_scores_gemma":[0.0000603025,0.0002394907,0.0008804607,0.02770089,0.0004887506,0.00113545,0.0001062141,0.0001373615,0.0002623334,0.00264626,0.966314,0.0000284935],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003682333,0.9993825,0.00003668641,0.0002063146,0.00009254992,0.000004213415,0.000008836958,0.000002004467,0.000230091],"genre_scores_gemma":[0.0002103318,0.9992979,0.0001067411,0.0001704652,0.00008586278,0.000005687311,0.00001153902,5.705828e-7,0.0001108875],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003151236,"threshold_uncertainty_score":0.01054192,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4321795635","doi":"10.1177/17588359231152843","title":"Quality of life with ribociclib <i>versus</i> abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Novartis (Canada)","funders":"National Cancer Institute; Eli Lilly and Company; Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Medicine; Breast cancer; Internal medicine; Quality of life (healthcare); Oncology; Placebo; Cancer; Hazard ratio; Clinical trial; Confidence interval; Alternative medicine; Pathology","authors":[{"name":"Hope S. Rugo","is_ca":false},{"name":"Victoria Harmer","is_ca":false},{"name":"Joyce O’Shaughnessy","is_ca":false},{"name":"Komal Jhaveri","is_ca":false},{"name":"Sara M. Tolaney","is_ca":false},{"name":"Fátima Cardoso","is_ca":false},{"name":"Aditya Bardia","is_ca":false},{"name":"Vikalp Kumar Maheshwari","is_ca":false},{"name":"Sandeep Tripathi","is_ca":false},{"name":"Sina Haftchenary","is_ca":true},{"name":"Purnima Pathak","is_ca":false},{"name":"Peter A. Fasching","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06506842105089145,"gpt":0.4343277424711693,"spread":0.3692593214202778,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004558647,0.00131513,0.003693532,0.0008582408,0.0001945566,0.001011486,0.001000503,0.001034181,0.006479251],"category_scores_gemma":[0.006086348,0.0004176467,0.007158555,0.0006510135,0.0005622237,0.0008331168,0.001007191,0.00173484,0.0003810218],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001282238,"about_ca_system_score_gemma":0.0008634902,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00160458,"about_ca_topic_score_gemma":0.002132027,"domain_scores_codex":[0.9949857,0.003473969,0.0004948797,0.0003729835,0.0004059461,0.0002665992],"domain_scores_gemma":[0.9962785,0.00193383,0.001120462,0.0002177556,0.0001846371,0.0002648573],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.9408383,0.001401455,0.004341665,0.003162768,0.02405036,0.00003385864,0.00007764095,0.001909557,0.0007301212,0.0004546657,0.000738028,0.02226164],"study_design_scores_gemma":[0.571004,0.2718502,0.06043581,0.001072023,0.07263499,0.0001874819,0.000253453,0.01164693,0.002402539,0.002740616,0.00561789,0.0001541074],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.972611,0.01393412,0.001472269,0.0003589603,0.0005541122,0.002556158,0.003695462,0.00006753881,0.004750501],"genre_scores_gemma":[0.9926583,0.001485696,0.001110336,0.0002423741,0.0001209364,0.002072775,0.00114509,0.00001039431,0.001154168],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006479251,"threshold_uncertainty_score":0.02410877,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4383647369","doi":"10.1177/17588359231183676","title":"Clinical trial reform in the post-COVID era","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Clinical trial; Medicine; Telehealth; Pandemic; Health care; Telemedicine; Coronavirus disease 2019 (COVID-19); Pathology; Political science; Disease","authors":[{"name":"Meghan E. Mahoney","is_ca":true},{"name":"Srikala S. Sridhar","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2428398450424699,"gpt":0.5987535896468035,"spread":0.3559137446043336,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.6591282,0.001047266,0.004458077,0.005292099,0.005346846,0.02568887,0.01165214,0.02012291,0.009748994],"category_scores_gemma":[0.7381485,0.001867441,0.00430095,0.009453451,0.02487774,0.02537953,0.01801429,0.02207351,0.001877473],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02740468,"about_ca_system_score_gemma":0.1191922,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004155727,"about_ca_topic_score_gemma":0.00542549,"domain_scores_codex":[0.2930938,0.6322193,0.02915551,0.01484878,0.02300562,0.007677066],"domain_scores_gemma":[0.12222,0.7493874,0.03668949,0.03355671,0.04134354,0.01680279],"domain_codex":"methods","domain_gemma":"methods","domain_candidate":"methods","domain_consensus":"methods","study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004060115,0.0006784043,0.004008165,0.04113694,0.00271765,0.0005771589,0.01419937,0.003577446,0.0006413925,0.290852,0.1042472,0.5333042],"study_design_scores_gemma":[0.008233426,0.00381467,0.01153896,0.05690127,0.001346751,0.000485815,0.005513493,0.002161977,0.0009246339,0.2078207,0.7009946,0.0002638475],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.01044373,0.1657764,0.01822219,0.7603042,0.01444888,0.006976114,0.0006267941,0.0003309048,0.02287079],"genre_scores_gemma":[0.1942807,0.0747912,0.07387414,0.589122,0.03030317,0.03062117,0.0009065224,0.0003900753,0.005711049],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.3408718,"threshold_uncertainty_score":0.4203556,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4408459343","doi":"10.1177/17588359251323985","title":"Immunotherapy in advanced, <i>KRAS</i> G12C-mutant non-small-cell lung cancer: current strategies and future directions","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"KRAS; Medicine; Cancer research; Blockade; Lung cancer; Cancer; Mutation; Immunotherapy; Mutant; Selumetinib; Oncology; Internal medicine; Biology; Colorectal cancer; Receptor","authors":[{"name":"Nadia Ghazali","is_ca":true},{"name":"Marina Chiara Garassino","is_ca":false},{"name":"Natasha B. Leighl","is_ca":true},{"name":"Christine M. Bestvina","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01673988495437135,"gpt":0.4375702361328022,"spread":0.4208303511784309,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003335439,0.0005618674,0.0009233139,0.001185442,0.000161542,0.0006864893,0.0005116377,0.0006345934,0.004076206],"category_scores_gemma":[0.0003258894,0.0001525589,0.0004403201,0.001048219,0.0002091966,0.0008530868,0.0004831663,0.001351603,0.001766167],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003207692,"about_ca_system_score_gemma":0.0005563129,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004629523,"about_ca_topic_score_gemma":0.001179989,"domain_scores_codex":[0.9999129,0.0000165412,0.00001141933,0.00001476959,0.00003211636,0.00001230915],"domain_scores_gemma":[0.9998884,0.00004892586,0.00001816502,0.00000314463,0.00003001768,0.00001129985],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007733626,0.00008428095,0.00007908602,0.01411168,0.00006856156,0.00008851413,0.00004146197,0.0003099714,0.00209115,0.002071293,0.0233381,0.9576386],"study_design_scores_gemma":[0.00003501682,0.0001751282,0.0005545906,0.003958958,0.0001185033,0.0007499461,0.00004378869,0.0001268874,0.0004676485,0.001502782,0.9922537,0.00001310424],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001710173,0.9982413,0.0001232716,0.0002531029,0.0001666041,0.000007155656,0.00002308445,0.000009178157,0.001005252],"genre_scores_gemma":[0.0006015851,0.9982579,0.0001629971,0.0001998261,0.0001054685,0.00000908349,0.00003365464,0.000001519748,0.0006279542],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004076206,"threshold_uncertainty_score":0.01363629,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4285270205","doi":"10.1177/17588359221094879","title":"The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Metastatic Urothelial Carcinoma; Medicine; Chemotherapy; Urothelial carcinoma; Oncology; Metastasis; Bone metastasis; Internal medicine; First line; Carcinoma; Cancer research; Cancer; Bladder cancer","authors":[{"name":"Husam Alqaisi","is_ca":true},{"name":"Carlos Stecca","is_ca":true},{"name":"Zachary Veitch","is_ca":true},{"name":"Jamila Riromar","is_ca":false},{"name":"Jeenan Kaiser","is_ca":false},{"name":"Nazanin Fallah‐Rad","is_ca":true},{"name":"Di Jiang","is_ca":true},{"name":"Scott North","is_ca":false},{"name":"Sunil Samnani","is_ca":false},{"name":"Nimira Alimohamed","is_ca":false},{"name":"Srikala S. Sridhar","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01586903876166198,"gpt":0.3268424962039521,"spread":0.3109734574422901,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004461207,0.0001618667,0.0002841593,0.0004831085,0.0003032086,0.0004881544,0.0003309251,0.0003103261,0.001277385],"category_scores_gemma":[0.002861512,0.0001251566,0.0003562394,0.0007096569,0.0001968152,0.0003842025,0.0002952877,0.0005025158,0.0001192842],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003778335,"about_ca_system_score_gemma":0.0003198024,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001813911,"about_ca_topic_score_gemma":0.003361382,"domain_scores_codex":[0.9997573,0.0000633107,0.00003079502,0.00003914941,0.00005983468,0.00004957055],"domain_scores_gemma":[0.9983442,0.000397021,0.0008637451,0.00004185918,0.0001108935,0.0002422662],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001199993,0.000008899124,0.9985942,0.000006994041,0.00001822109,0.00008927639,0.000009993261,0.00003166389,0.00009138192,0.000004976204,0.00004008612,0.0009841671],"study_design_scores_gemma":[0.000009199252,0.0001061164,0.9985291,0.000007244482,0.00003237809,0.0008508907,0.00005687835,0.0001851718,0.0000711672,0.00001538085,0.0001344967,0.00000195209],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986651,0.0008017101,0.00004489452,0.00006222212,0.00000510206,0.000004772362,0.0001535529,0.000001985675,0.000260589],"genre_scores_gemma":[0.9996874,0.0001103603,0.00003208998,0.00001294386,0.000008591619,0.000002540334,0.000110883,6.274124e-7,0.00003460815],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001813911,"threshold_uncertainty_score":0.004273295,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2118364274","doi":"10.1177/1758834012438214","title":"Exemestane in the prevention setting","year":2012,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Exemestane; Medicine; Breast cancer; Aromatase; Oncology; Adjuvant; Internal medicine; Clinical trial; Cancer; Gynecology","authors":[{"name":"Jennifer K. Litton","is_ca":false},{"name":"Therese B. Bevers","is_ca":false},{"name":"Banu Arun","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01053476753346444,"gpt":0.3565464966087671,"spread":0.3460117290753027,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004647118,0.0001662466,0.0003611937,0.0003572941,0.000191802,0.0005840787,0.0002381245,0.0006197648,0.002683945],"category_scores_gemma":[0.0009839502,0.00008349047,0.000277473,0.0003030058,0.0002134011,0.0005417693,0.0002970463,0.0009979036,0.0009497576],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002667092,"about_ca_system_score_gemma":0.0005499463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002822283,"about_ca_topic_score_gemma":0.0006516842,"domain_scores_codex":[0.9997823,0.0000831018,0.0000309257,0.0000283853,0.00005833435,0.00001706689],"domain_scores_gemma":[0.9995546,0.0002297979,0.0001081858,0.00001675369,0.0000521885,0.00003846407],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.001162419,0.0001940031,0.003815919,0.005754329,0.0001100471,0.002622562,0.0001782321,0.0003128477,0.008346501,0.0119052,0.01797077,0.9476272],"study_design_scores_gemma":[0.0002262824,0.001106085,0.006090835,0.003850958,0.0002591606,0.01591906,0.0001952299,0.0001506424,0.008834872,0.009147926,0.9541919,0.00002714655],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.00640625,0.9746249,0.0008778271,0.004303668,0.0005564048,0.00001790635,0.0000758328,0.00001967475,0.0131176],"genre_scores_gemma":[0.09556454,0.8879734,0.002301033,0.004210174,0.00237028,0.00003473081,0.0001272137,0.00001042809,0.00740825],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.002683945,"threshold_uncertainty_score":0.008978665,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3211652415","doi":"10.1177/17588359211056306","title":"The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; University of Ottawa; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; William Osler Health System; McMaster University; Ottawa Hospital; University Health Network; Dalhousie University; University of Toronto; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"AstraZeneca Canada; Pfizer","keywords":"Medicine; Lung cancer; Adjuvant; Oncology; Internal medicine; Cancer research; Pathology","authors":[{"name":"Barbara Melosky","is_ca":true},{"name":"Parneet Cheema","is_ca":true},{"name":"Rosalyn A. Juergens","is_ca":true},{"name":"Natasha B. Leighl","is_ca":true},{"name":"Geoffrey Liu","is_ca":true},{"name":"Paul Wheatley‐Price","is_ca":true},{"name":"Adrian G. Sacher","is_ca":true},{"name":"Stephanie Snow","is_ca":true},{"name":"Ming‐Sound Tsao","is_ca":true},{"name":"Deanna McLeod","is_ca":false},{"name":"Quincy S. Chu","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03545036681411599,"gpt":0.4610218157840545,"spread":0.4255714489699385,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001793502,0.0001790208,0.0006928899,0.0009911569,0.0001268469,0.0009823926,0.0003051298,0.0008991517,0.002823002],"category_scores_gemma":[0.003152124,0.0001273817,0.0005577384,0.001418992,0.0004180388,0.002153007,0.0003012832,0.001228433,0.0003617285],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007755935,"about_ca_system_score_gemma":0.001459013,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001064921,"about_ca_topic_score_gemma":0.003016194,"domain_scores_codex":[0.9996409,0.0001277824,0.00008571428,0.00004018788,0.00008453555,0.00002087896],"domain_scores_gemma":[0.9979018,0.001360758,0.0003413835,0.00004726831,0.0002586011,0.00009013037],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009460133,0.00007839064,0.00125693,0.02513442,0.0001658829,0.0002482278,0.0001251682,0.0002851695,0.002562817,0.00657429,0.05435927,0.9082634],"study_design_scores_gemma":[0.0006789431,0.00125243,0.009736227,0.03216433,0.0009374097,0.002371696,0.0003986692,0.0004310039,0.001309236,0.01141809,0.9392556,0.00004639061],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001984927,0.9866287,0.0001975156,0.008822487,0.000937343,0.000009517345,0.0001016861,0.00001095279,0.001306789],"genre_scores_gemma":[0.02048404,0.9687816,0.000803953,0.006174115,0.002602133,0.00001878839,0.0001635674,0.000007535913,0.0009642952],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002823002,"threshold_uncertainty_score":0.009485066,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3208960913","doi":"10.1177/17588359211051870","title":"Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Systemic therapy; Hormone therapy; Internal medicine; Clinical trial; Radiation therapy; Prostate-specific antigen; Disease; Cancer; Breast cancer","authors":[{"name":"Anna Patrikidou","is_ca":false},{"name":"Thomas Zilli","is_ca":false},{"name":"Giulia Baciarello","is_ca":false},{"name":"Safae Terisse","is_ca":false},{"name":"Zineb Hamilou","is_ca":true},{"name":"Karim Fizazi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1020539174751776,"gpt":0.459568545127229,"spread":0.3575146276520514,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007699266,0.0004181193,0.001541209,0.001121106,0.0002080245,0.000778784,0.0007894013,0.001188794,0.003953525],"category_scores_gemma":[0.001240947,0.0001795689,0.0007611753,0.001062036,0.0004215056,0.001303333,0.0003488543,0.001916299,0.001650871],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003530427,"about_ca_system_score_gemma":0.001038451,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001059894,"about_ca_topic_score_gemma":0.003202992,"domain_scores_codex":[0.9997879,0.00006719904,0.00003440479,0.00002759416,0.00006600484,0.00001691313],"domain_scores_gemma":[0.9995827,0.0002303533,0.00006594241,0.00001163554,0.00008553552,0.00002389192],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001628762,0.00005299928,0.0001481324,0.01806607,0.0001490739,0.0001343131,0.00005092358,0.0001425398,0.0004936071,0.00218715,0.02818515,0.9502273],"study_design_scores_gemma":[0.0001257235,0.0002156995,0.001434265,0.0144125,0.0003173158,0.001831886,0.0001176716,0.00008469243,0.0002403417,0.003218671,0.9779747,0.00002664251],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00008500451,0.9985414,0.00004710019,0.0006692614,0.0001948274,0.0000032087,0.00001174677,0.000002875852,0.0004445763],"genre_scores_gemma":[0.0007573651,0.9977011,0.0001553754,0.0007477389,0.0002603251,0.000006432159,0.00002533427,0.000001452451,0.000344945],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003953525,"threshold_uncertainty_score":0.01322585,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4312211783","doi":"10.1177/17588359221143975","title":"Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"BC Cancer Foundation; Michael Smith Health Research BC","keywords":"Medicine; Liquid biopsy; Colorectal cancer; Stage (stratigraphy); Oncology; Minimal residual disease; Circulating tumor DNA; Internal medicine; Cancer; Clinical trial; Disease; Adjuvant; Leukemia","authors":[{"name":"João Paulo Solar Vasconcelos","is_ca":true},{"name":"Mélina Boutin","is_ca":true},{"name":"Jonathan M. Loree","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06832000875268691,"gpt":0.4248725844434207,"spread":0.3565525756907338,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00916246,0.00059647,0.002932292,0.00166929,0.0005477672,0.003270323,0.001548193,0.003498001,0.002882189],"category_scores_gemma":[0.03724001,0.0005740506,0.001575768,0.001444341,0.00225056,0.006855592,0.001084507,0.004993686,0.001604531],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001647266,"about_ca_system_score_gemma":0.002951075,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003660252,"about_ca_topic_score_gemma":0.00533723,"domain_scores_codex":[0.9955776,0.001961755,0.0008938126,0.0004165734,0.0009745077,0.0001758582],"domain_scores_gemma":[0.9702995,0.01957477,0.002055306,0.0005932319,0.006750379,0.0007267917],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008188094,0.00004798469,0.01184006,0.01566754,0.000508389,0.0007574009,0.0005565368,0.0002558555,0.001202148,0.009737941,0.09748758,0.8611198],"study_design_scores_gemma":[0.0001870759,0.000732049,0.01456757,0.03901007,0.00177193,0.006411377,0.002760252,0.0008578065,0.001711295,0.03260994,0.899128,0.0002526765],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001191032,0.9286492,0.002476709,0.06241139,0.004155666,0.00002226442,0.000105753,0.00004598965,0.0009420172],"genre_scores_gemma":[0.02003318,0.9080151,0.00957526,0.04236982,0.01773235,0.00008855245,0.0002647866,0.00007357165,0.001847411],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00916246,"threshold_uncertainty_score":0.04845625,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}